
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Influence of the gut microbiome on lymphoma treatment: current evidence and future therapeutic directions - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15254EE68AF3EA53054EE6004E5BC8BC.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="tam">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Therapeutic Advances in Medical Oncology">
<meta name="citation_title" content="Influence of the gut microbiome on lymphoma treatment: current evidence and future therapeutic directions">
<meta name="citation_author" content="Jiajie Tu">
<meta name="citation_author_institution" content="Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China">
<meta name="citation_author_institution" content="National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China">
<meta name="citation_author_institution" content="Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China">
<meta name="citation_author" content="Lingzi Yu">
<meta name="citation_author_institution" content="Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China">
<meta name="citation_author_institution" content="National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China">
<meta name="citation_author_institution" content="Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China">
<meta name="citation_author" content="Rui Zou">
<meta name="citation_author_institution" content="Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China">
<meta name="citation_author_institution" content="National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China">
<meta name="citation_author_institution" content="Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China">
<meta name="citation_author" content="Jiajie He">
<meta name="citation_author_institution" content="Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China">
<meta name="citation_author_institution" content="National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China">
<meta name="citation_author_institution" content="Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China">
<meta name="citation_author" content="Changju Qu">
<meta name="citation_author_institution" content="Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou 215000, China">
<meta name="citation_author_institution" content="National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China">
<meta name="citation_author_institution" content="Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215000, China">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="17">
<meta name="citation_firstpage" content="17588359251363207">
<meta name="citation_doi" content="10.1177/17588359251363207">
<meta name="citation_pmid" content="40842975">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/pdf/10.1177_17588359251363207.pdf">
<meta name="description" content="The heterogeneity of lymphoma responses to various treatments remains a significant challenge in clinical practice. Emerging evidence implicates the potential role of the gut microbiome in lymphoma pathogenesis and progression. Advances in ...">
<meta name="og:title" content="Influence of the gut microbiome on lymphoma treatment: current evidence and future therapeutic directions">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The heterogeneity of lymphoma responses to various treatments remains a significant challenge in clinical practice. Emerging evidence implicates the potential role of the gut microbiome in lymphoma pathogenesis and progression. Advances in ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12365434">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1177/17588359251363207"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/10.1177_17588359251363207.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365434%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12365434/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12365434/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-tam.png" alt="Therapeutic Advances in Medical Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Therapeutic Advances in Medical Oncology" title="Link to Therapeutic Advances in Medical Oncology" shape="default" href="http://tam.sagepub.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Ther Adv Med Oncol</button></div>. 2025 Aug 19;17:17588359251363207. doi: <a href="https://doi.org/10.1177/17588359251363207" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1177/17588359251363207</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Ther%20Adv%20Med%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ther%20Adv%20Med%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Ther%20Adv%20Med%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Ther%20Adv%20Med%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Influence of the gut microbiome on lymphoma treatment: current evidence and future therapeutic directions</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tu%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jiajie Tu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jiajie Tu</span></h3>
<div class="p">
<sup>1</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div class="p">
<sup>2</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div class="p">
<sup>3</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div>Conceptualization, Visualization, Writing – original draft</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tu%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiajie Tu</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Lingzi Yu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Lingzi Yu</span></h3>
<div class="p">
<sup>4</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div class="p">
<sup>5</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div class="p">
<sup>6</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div>Conceptualization, Writing – original draft</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yu%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lingzi Yu</span></a>
</div>
</div>
<sup>4,</sup><sup>5,</sup><sup>6,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zou%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Rui Zou</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Rui Zou</span></h3>
<div class="p">
<sup>7</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div class="p">
<sup>8</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div class="p">
<sup>9</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div>Conceptualization, Methodology</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zou%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Rui Zou</span></a>
</div>
</div>
<sup>7,</sup><sup>8,</sup><sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jiajie He</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jiajie He</span></h3>
<div class="p">
<sup>10</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div class="p">
<sup>11</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div class="p">
<sup>12</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div>Conceptualization, Investigation</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22He%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiajie He</span></a>
</div>
</div>
<sup>10,</sup><sup>11,</sup><sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qu%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Changju Qu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Changju Qu</span></h3>
<div class="p">
<sup>13</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou 215000, China</div>
<div class="p">
<sup>14</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China</div>
<div class="p">
<sup>15</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215000, China</div>
<div>Conceptualization, Supervision, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qu%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Changju Qu</span></a>
</div>
</div>
<sup>13,</sup><sup>14,</sup><sup>15,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1-17588359251363207">
<sup>1</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div id="aff2-17588359251363207">
<sup>2</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div id="aff3-17588359251363207">
<sup>3</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div id="aff4-17588359251363207">
<sup>4</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div id="aff5-17588359251363207">
<sup>5</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div id="aff6-17588359251363207">
<sup>6</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div id="aff7-17588359251363207">
<sup>7</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div id="aff8-17588359251363207">
<sup>8</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div id="aff9-17588359251363207">
<sup>9</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div id="aff10-17588359251363207">
<sup>10</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China</div>
<div id="aff11-17588359251363207">
<sup>11</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China</div>
<div id="aff12-17588359251363207">
<sup>12</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China</div>
<div id="aff13-17588359251363207">
<sup>13</sup>Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou 215000, China</div>
<div id="aff14-17588359251363207">
<sup>14</sup>National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China</div>
<div id="aff15-17588359251363207">
<sup>15</sup>Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215000, China</div>
<div class="author-notes p">
<div class="fn" id="corresp1-17588359251363207">
<sup>✉</sup><p class="display-inline">Email: <span>qcj310@163.com</span></p>
</div>
<div class="fn" id="fn1-17588359251363207">
<sup>*</sup><p class="display-inline">These authors contributed equally</p>
</div>
</div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Jiajie Tu</span></strong>: <span class="role">Conceptualization, Visualization, Writing – original draft</span>
</div>
<div>
<strong class="contrib"><span class="name western">Lingzi Yu</span></strong>: <span class="role">Conceptualization, Writing – original draft</span>
</div>
<div>
<strong class="contrib"><span class="name western">Rui Zou</span></strong>: <span class="role">Conceptualization, Methodology</span>
</div>
<div>
<strong class="contrib"><span class="name western">Jiajie He</span></strong>: <span class="role">Conceptualization, Investigation</span>
</div>
<div>
<strong class="contrib"><span class="name western">Changju Qu</span></strong>: <span class="role">Conceptualization, Supervision, Writing – review &amp; editing</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 30; Accepted 2025 Jul 10; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s), 2025</div>
<p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by-nc/4.0/</a>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<a href="https://us.sagepub.com/en-us/nam/open-access-at-sage" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://us.sagepub.com/en-us/nam/open-access-at-sage</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12365434  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40842975/" class="usa-link">40842975</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>The heterogeneity of lymphoma responses to various treatments remains a significant challenge in clinical practice. Emerging evidence implicates the potential role of the gut microbiome in lymphoma pathogenesis and progression. Advances in high-throughput sequencing and metabolomics have significantly enhanced our understanding of the complex interaction between the gut microbiome and lymphoma. Although causality requires further elucidation, the gut microbiome critically shapes host responses to traditional combined chemotherapy, hematopoietic stem cell transplantation, and targeted therapies, including chimeric antigen receptor T-cell therapy. Notably, the use of antibiotics, particularly broad-spectrum antibiotics, can alter the gut microbiome, thereby impacting treatment efficacy. Prudent antibiotic management should balance infection control with microbiome-dependent immune homeostasis. Strategies to restore gut microbial balance through a high-fiber diet, probiotics, prebiotics, fecal microbiota transplantation, and butyrate supplementation are critically important. Integrating microbiome-based therapies into lymphoma treatment could establish low-toxicity therapeutic paradigms for lymphoma patients.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> antibiotic management, gut metabolites, gut microbiome, lymphoma, microbiome therapy</p></section></section><section class="abstract" id="abstract2"><h2>Plain language summary</h2>
<p>
How gut bacteria affect lymphoma treatment: what we know and future possibilities
</p>
<p>Lymphoma treatments often work differently for each patient, and scientists now believe the community of bacteria in our gut may help explain these variations. Research shows these bacteria influence common lymphoma therapies like chemotherapy, stem cell transplants, and CAR-T cell treatment. Problems arise when antibiotics disrupt this delicate bacterial balance, possibly reducing treatment effectiveness. Doctors are now exploring ways to protect helpful gut bacteria while preventing infections. New approaches include special diets, probiotic supplements, and even microbiota transplants that may boost treatment success. These discoveries could lead to more personalized lymphoma therapies with better results and fewer side effects, offering new hope for lymphoma patients.</p></section><section id="section1-17588359251363207"><h2 class="pmc_sec_title">Background</h2>
<p>Lymphoma, originating in lymph nodes or other lymphoid tissues, is a group of immune system malignancies. In recent years, lymphoma has presented a persistently increasing incidence.<sup><a href="#bibr1-17588359251363207" class="usa-link" aria-describedby="bibr1-17588359251363207">1</a>,<a href="#bibr2-17588359251363207" class="usa-link" aria-describedby="bibr2-17588359251363207">2</a></sup> Despite advances in treatment, the development of drug resistance in certain patients has led to suboptimal responses, while the limited availability of effective therapies for relapsed/refractory (R/R) lymphoma remains a major clinical challenge.<sup><a href="#bibr3-17588359251363207" class="usa-link" aria-describedby="bibr3-17588359251363207">3</a>,<a href="#bibr4-17588359251363207" class="usa-link" aria-describedby="bibr4-17588359251363207">4</a></sup> In addition, the toxicity associated with conventional treatments often results in severe adverse effects, significantly compromising patients’ quality of life.<sup>
<a href="#bibr5-17588359251363207" class="usa-link" aria-describedby="bibr5-17588359251363207">5</a>
</sup> Given these challenges, there is an urgent need to elucidate the key mechanisms driving lymphoma progression and to identify clinically relevant biomarkers and therapeutic targets, which are critical for developing more effective and less toxic treatment strategies.</p>
<p>The gastrointestinal (GI) tract hosts a complex microbial ecosystem, comprising bacteria, archaea (single-celled organisms without nuclei), fungi, and microbial eukaryotes. In healthy individuals, the gut microbiota is dominated by five primary bacterial phyla: <em>Firmicutes</em> (79.4%), <em>Bacteroidetes</em> (16.9%), <em>Actinobacteria</em> (2.5%), <em>Proteobacteria</em> (1%), and <em>Verrucomicrobia</em> (0.1%).<sup>
<a href="#bibr6-17588359251363207" class="usa-link" aria-describedby="bibr6-17588359251363207">6</a>
</sup> Under normal conditions, these microbes aid in digestion and support immune function,<sup>
<a href="#bibr7-17588359251363207" class="usa-link" aria-describedby="bibr7-17588359251363207">7</a>
</sup> but when malfunctioning, the abnormal composition and function of the microbiota are strongly associated with the development of a variety of diseases, such as inflammation, autoimmune diseases, metabolic, and neoplastic diseases.<sup><a href="#bibr8-17588359251363207" class="usa-link" aria-describedby="bibr8-17588359251363207">8</a>
–<a href="#bibr11-17588359251363207" class="usa-link" aria-describedby="bibr11-17588359251363207">11</a></sup></p>
<p>Growing evidence<sup>
<a href="#bibr12-17588359251363207" class="usa-link" aria-describedby="bibr12-17588359251363207">12</a>
</sup> suggests a consistent link between gut microbiota and lymphoma. Shi and Zhang proposed the concept of the “microbiota-gut-lymphoma axis”<sup>
<a href="#bibr13-17588359251363207" class="usa-link" aria-describedby="bibr13-17588359251363207">13</a>
</sup> indicating that specific gut microbial taxa may influence the risk of different lymphoma subtypes. Here, we propose that alterations in the gut microbiota composition contribute to the onset and progression of lymphoma, and specific microbial taxa may serve as both biomarkers for disease development and potential targets for personalized, low-toxicity therapeutic interventions. However, the exact cause-and-effect relationship between gut microbiota and lymphoma remains undefined. Systematic characterization of microbiome-host interplay during disease progression could identify novel diagnostic and prognostic biomarkers, thereby establishing a framework for precision management and therapeutic innovation.</p></section><section id="section2-17588359251363207"><h2 class="pmc_sec_title">Materials and methods</h2>
<p>This narrative review is based on the relevant PubMed literature. The main search terms include “lymphoma,” “lymphocyte,” “gut microbiota/microbiome,” “microbial dysbiosis,” “antibiotic,” and “short-chain fatty acids (SCFAs)” combined with Boolean operators AND/OR. The search encompassed literature published until May 2025. The initial search yielded a total of 132 articles. The inclusion criteria were articles that study the gut microbiome in lymphoma. Given the narrative nature of this review, formal evidence grading was not performed. We included all available study designs, predominantly observational studies, along with clinical and preclinical trials. Case reports were restricted to rare clinical scenarios. Sixty-one articles were selected for full-text review. The data, including microbial characteristics, intervention details, main outcomes, and mechanistic roles of gut microbiota, were extracted and analyzed.</p></section><section id="section3-17588359251363207"><h2 class="pmc_sec_title">Gut microbiome dysbiosis across lymphoma subtypes</h2>
<p>Wotherspoon et al.<sup><a href="#bibr14-17588359251363207" class="usa-link" aria-describedby="bibr14-17588359251363207">14</a>,<a href="#bibr15-17588359251363207" class="usa-link" aria-describedby="bibr15-17588359251363207">15</a></sup> found that more than 90% of gastric mucosa-associated lymphoid tissue (MALT) lymphoma patients harbored <em>Helicobacter pylori</em> (HP) in their gastric mucosa, and HP eradication led to complete remission (CR) in five out of six cases. Subsequent studies have identified HP as an etiologic factor in gastric MALT lymphoma.<sup>
<a href="#bibr16-17588359251363207" class="usa-link" aria-describedby="bibr16-17588359251363207">16</a>
</sup> Antibiotics have shown potential efficacy in treating certain lymphoma cases.<sup>
<a href="#bibr15-17588359251363207" class="usa-link" aria-describedby="bibr15-17588359251363207">15</a>
</sup> However, their broad-spectrum activity may simultaneously disrupt commensal microbiota. Yuan et al.<sup>
<a href="#bibr17-17588359251363207" class="usa-link" aria-describedby="bibr17-17588359251363207">17</a>
</sup> observed that patients with diffuse large B-cell lymphoma (DLBCL) exhibited elevated levels of <em>Escherichia-Shigella</em>, <em>Enterococcus</em>, <em>Veillonella</em>, and <em>Prevotella-2</em> compared to healthy controls. Yoon et al.<sup>
<a href="#bibr18-17588359251363207" class="usa-link" aria-describedby="bibr18-17588359251363207">18</a>
</sup> reported decreased alpha-diversity in the gut microbiota of newly diagnosed DLBCL patients, alongside an increased abundance of <em>Enterobacteriaceae</em>. Xu et al.<sup>
<a href="#bibr19-17588359251363207" class="usa-link" aria-describedby="bibr19-17588359251363207">19</a>
</sup> reported that <em>Fusobacteria</em> were increased in primary DLBCL patients compared to healthy controls across all taxonomic levels (phylum to species), while <em>Enterococcus</em> predominated in R/R patients. In patients with cutaneous T-cell lymphoma, Hooper et al.<sup>
<a href="#bibr20-17588359251363207" class="usa-link" aria-describedby="bibr20-17588359251363207">20</a>
</sup> found that the diversity of the gut microbiota was reduced, with a significant decrease observed in advanced disease stages and specific bacterial taxa exhibiting altered abundance, and the gut microbiota may further modulate the response of narrowband ultraviolet B (a common skin-directed therapy).<sup>
<a href="#bibr21-17588359251363207" class="usa-link" aria-describedby="bibr21-17588359251363207">21</a>
</sup> In patients with mycosis fungoides, their latest findings identified a decrease in SCFAs production, suggesting that microbial metabolic changes may underlie variations in therapeutic response.<sup>
<a href="#bibr22-17588359251363207" class="usa-link" aria-describedby="bibr22-17588359251363207">22</a>
</sup> Chiba et al.<sup>
<a href="#bibr23-17588359251363207" class="usa-link" aria-describedby="bibr23-17588359251363207">23</a>
</sup> reported that <em>Klebsiella</em> exhibited significant enrichment in patients with adult T-cell leukemia/lymphoma. Patients with GI follicular lymphoma (FL) also displayed altered duodenal mucosal flora.<sup>
<a href="#bibr24-17588359251363207" class="usa-link" aria-describedby="bibr24-17588359251363207">24</a>
</sup> Xu et al.<sup>
<a href="#bibr25-17588359251363207" class="usa-link" aria-describedby="bibr25-17588359251363207">25</a>
</sup> demonstrated that patients with FL exhibited unique microbiota compositions, characterized by a notable increase in the relative abundance of the <em>Ruminococcaceae</em> family. Kang et al.<sup>
<a href="#bibr26-17588359251363207" class="usa-link" aria-describedby="bibr26-17588359251363207">26</a>
</sup> found that primary central nervous system lymphoma (PCNSL) patients exhibited significantly increased <em>Proteobacteria</em> abundance and an elevated <em>Firmicutes/Bacteroidetes</em> ratio—a recognized signature of gut dysbiosis. Several Mendelian randomization evidence revealed preliminary causal links between gut microbiota and lymphoma. The genus <em>Ruminococcaceae UCG002</em><sup><a href="#bibr27-17588359251363207" class="usa-link" aria-describedby="bibr27-17588359251363207">27</a>,<a href="#bibr28-17588359251363207" class="usa-link" aria-describedby="bibr28-17588359251363207">28</a></sup> may be linked to an increased risk of DLBCL, while the genera <em>Alistipes</em><sup><a href="#bibr28-17588359251363207" class="usa-link" aria-describedby="bibr28-17588359251363207">28</a>,<a href="#bibr29-17588359251363207" class="usa-link" aria-describedby="bibr29-17588359251363207">29</a></sup> and <em>Turicibacter</em><sup>
<a href="#bibr28-17588359251363207" class="usa-link" aria-describedby="bibr28-17588359251363207">28</a>
</sup> may exert protective effects. <em>Veillonella</em> may be linked to an increased risk of Hodgkin lymphoma (HL),<sup>
<a href="#bibr30-17588359251363207" class="usa-link" aria-describedby="bibr30-17588359251363207">30</a>
</sup> while <em>Faecalibacterium prausnitzii</em> may exert protective effects.<sup>
<a href="#bibr31-17588359251363207" class="usa-link" aria-describedby="bibr31-17588359251363207">31</a>
</sup> Phylum <em>Bacteroidetes</em> may be associated with lymphoma.<sup>
<a href="#bibr32-17588359251363207" class="usa-link" aria-describedby="bibr32-17588359251363207">32</a>
</sup> Notably, <em>Alistipes</em> exhibits a bidirectional interaction with DLBCL: it may protect against lymphomagenesis, yet its abundance is increased in DLBCL patients,<sup>
<a href="#bibr28-17588359251363207" class="usa-link" aria-describedby="bibr28-17588359251363207">28</a>
</sup> possibly reflecting disease-driven dysbiosis or compensatory microbial adaptation. However, given the inherent complexity of gut microbial ecosystems and current limitations in genome-wide association study coverage, these results require further validation.</p></section><section id="section4-17588359251363207"><h2 class="pmc_sec_title">Influence of gut microbiome on lymphoma treatment</h2>
<section id="section5-17588359251363207"><h3 class="pmc_sec_title">Traditional combined chemotherapy</h3>
<p>Traditional combined chemotherapy is a classical therapeutic approach for lymphoma patients. However, there is still a considerable portion of patients who fail to achieve remission due to chemoresistance. Growing evidence highlights the critical role of the gut microbiome in modulating the host’s antilymphoma response, potentially enhancing or diminishing the efficacy of chemotherapy. Nausea and vomiting are frequent side effects that can significantly impair patients’ quality of life during the treatments. In addition, patients often suffer a high risk of febrile neutropenia after chemotherapy, which can cause treatment delay, dose reduction, or even fatal infection. Maintaining gut microbial homeostasis appears critical for modulating febrile neutropenia risk, as specific compositional changes are associated with increased risk, while a balanced microbiota may confer protective effects. Incorporating gut microbiota modulation into therapeutic strategies could improve treatment tolerance and prognostic outcomes.</p>
<section id="section6-17588359251363207"><h4 class="pmc_sec_title">Influence of gut microbiota and its metabolites on chemotherapy of lymphoma</h4>
<p>Diefenbach et al.<sup>
<a href="#bibr33-17588359251363207" class="usa-link" aria-describedby="bibr33-17588359251363207">33</a>
</sup> found that the gut microbiota significantly differed between the chemotherapy responders and nonresponders. Xu et al.<sup>
<a href="#bibr34-17588359251363207" class="usa-link" aria-describedby="bibr34-17588359251363207">34</a>
</sup> found that patients with DLBCL who achieved CR after combined chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment exhibited a higher abundance of family <em>Veillonellaceae</em> both before and after the treatment, while patients without CR exhibited a higher abundance of family <em>Rikenellaceae</em>. The results suggested that the abundance of <em>Veillonellaceae</em> and <em>Rikenellaceae</em> may correlate with outcomes of R-CHOP therapy in DLBCL patients. Another finding was that the presence of <em>Lactobacillus fermentum</em> was associated with more favorable treatment outcomes. While elevated <em>Alistipes</em> levels seem linked to worse treatment response, the overall evidence indicates mixed views. Another study conducted by Yoon et al.<sup>
<a href="#bibr18-17588359251363207" class="usa-link" aria-describedby="bibr18-17588359251363207">18</a>
</sup> suggested that a higher abundance of <em>Enterobacteriaceae</em> at the family level correlated with a shorter progression-free survival (PFS), higher risk of febrile neutropenia, and greater likelihood of relapse and progression. Restoring gut microbiota balance may reduce <em>Enterobacteriaceae</em> overgrowth, potentially lowering febrile neutropenia risk and improving outcomes. Moreover, Hernández-Verdin et al.<sup>
<a href="#bibr35-17588359251363207" class="usa-link" aria-describedby="bibr35-17588359251363207">35</a>
</sup> were the first to report that in PCNSL patients, higher <em>Parabacteroides distasonis</em> abundance and plasma betaine–valine levels were positively associated with prolonged PFS and overall survival (OS). In conclusion, the diversity and composition of gut microbiota correlate with the efficacy of chemotherapy (summarized in <a href="#table1-17588359251363207" class="usa-link">Table 1</a>). Although the specific role of gut microbial metabolites in lymphoma chemotherapy remains not fully explored, mechanistic insights may be extrapolated from other malignancies. He et al.<sup>
<a href="#bibr36-17588359251363207" class="usa-link" aria-describedby="bibr36-17588359251363207">36</a>
</sup> found that patients with GI cancer responding to oxaliplatin therapy had significantly higher serum levels of butyrate compared to nonresponders. Butyrate acts as a histone deacetylase (HDAC) inhibitor to modulate CD8 T-cell function and enhance antitumor efficacy. This mechanism may be relevant to lymphoma therapy, as oxaliplatin—used in rituximab, gemcitabine, and oxaliplatin regimen for R/R DLBCL—also relies on T-cell-mediated cytotoxicity.</p>
<section class="tw xbox font-sm" id="table1-17588359251363207"><h5 class="obj_head">Table 1.</h5>
<div class="caption p"><p>Clinical efficacy and gut microbiome in combined chemotherapy-treated patients.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">First author</th>
<th align="left" rowspan="1" colspan="1">Regimen</th>
<th align="left" rowspan="1" colspan="1">Disease</th>
<th align="left" rowspan="1" colspan="1">Patient, <em>n</em> (%)</th>
<th align="left" rowspan="1" colspan="1">Treatment response, <em>n</em>(%)</th>
<th align="left" rowspan="1" colspan="1">Positive microbiota-related factors</th>
<th align="left" rowspan="1" colspan="1">Negative microbiota-related factors</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Diefenbach et al.<sup>
<a href="#bibr33-17588359251363207" class="usa-link" aria-describedby="bibr33-17588359251363207">33</a>
</sup>
</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">DLBCL</td>
<td rowspan="1" colspan="1">8(57)</td>
<td rowspan="1" colspan="1">CR/PR, 8(57)</td>
<td rowspan="1" colspan="1">
<em>Dorea formicigenerans</em>, <em>Faecalibacterium prausnitzii</em>
</td>
<td rowspan="1" colspan="1">Reduced alpha-diversity</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">FL, MCL</td>
<td rowspan="1" colspan="1">6(43)</td>
<td rowspan="1" colspan="1">NR, 6(43)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Xu et al.<sup>
<a href="#bibr34-17588359251363207" class="usa-link" aria-describedby="bibr34-17588359251363207">34</a>
</sup>
</td>
<td rowspan="1" colspan="1">R-CHOP based</td>
<td rowspan="1" colspan="1">DLBCL</td>
<td rowspan="1" colspan="1">17(100)</td>
<td rowspan="1" colspan="1">CR, 10(59)</td>
<td rowspan="1" colspan="1">Family <em>Lactobacillaceae</em>, genus <em>Lactobacillus</em>, genus <em>Veillonella</em>
</td>
<td rowspan="1" colspan="1">Family <em>Rikenellaceae</em>, genus <em>Alistipes</em>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">NCR, 7(41)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Yoon et al.<sup>
<a href="#bibr18-17588359251363207" class="usa-link" aria-describedby="bibr18-17588359251363207">18</a>
</sup>
</td>
<td rowspan="1" colspan="1">R-CHOP</td>
<td rowspan="1" colspan="1">DLBCL</td>
<td rowspan="1" colspan="1">158(100)</td>
<td rowspan="1" colspan="1">CR, 146(92)</td>
<td rowspan="1" colspan="1">
<em>Prevotellaceae</em>, <em>Oscillospiraceae</em>
</td>
<td rowspan="1" colspan="1">
<em>Enterobacteriaceae</em>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">PR, 8(5)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">PD, 4(3)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hernández-Verdin et al.<sup>
<a href="#bibr35-17588359251363207" class="usa-link" aria-describedby="bibr35-17588359251363207">35</a>
</sup>
</td>
<td rowspan="1" colspan="1">HD-MTX-based polychemotherapy</td>
<td rowspan="1" colspan="1">PCNSL</td>
<td rowspan="1" colspan="1">40(100)</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">
<em>Parabacteroides distasonis</em>, betaine–valine</td>
<td rowspan="1" colspan="1">–</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table1-17588359251363207/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn1-17588359251363207"><p>CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HD-MTX, high-dose methotrexate; MCL, mantle cell lymphoma; NCR, non-complete response; NR, no response; PCNSL, primary central nervous system lymphoma; PD, progressive disease; PR, partial response; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.</p></div></div></section></section><section id="section7-17588359251363207"><h4 class="pmc_sec_title">Influence of antibiotic management on chemotherapy of lymphoma</h4>
<p>Bloodstream infection continues to be a significant contributor to non-relapse mortality among patients experiencing chemotherapy-induced neutropenia. The empirical administration of broad-spectrum antibiotics remains a fundamental aspect of supportive care in lymphoma. It was reported that translocation of gram-positive bacteria into the secondary lymphoid organs caused by cyclophosphamide, a component of the R-CHOP regimen, could promote the generation of pathogenic T helper cell 17 (Th17) cells and memory T helper cell 1 (Th1) immune responses, thereby contributing positively to its antilymphoma effects. However, anti-gram-positive antibiotics will reduce the level of the pathogenic Th17 cells, thus diminishing the antilymphoma effect of chemotherapy.<sup>
<a href="#bibr37-17588359251363207" class="usa-link" aria-describedby="bibr37-17588359251363207">37</a>
</sup> Moreover, Pflug et al.<sup>
<a href="#bibr38-17588359251363207" class="usa-link" aria-describedby="bibr38-17588359251363207">38</a>
</sup> demonstrated that treating relapsed lymphoma patients with anti-gram-positive antibiotics was associated with earlier disease progression, reduced PFS, and worse OS. These findings underscore the importance of understanding the broader implications of antibiotic use in lymphoma management and highlight the need for targeted bacteriotherapy strategies that leverage specific bacterial species or strains to optimize chemotherapy outcomes.<sup>
<a href="#bibr39-17588359251363207" class="usa-link" aria-describedby="bibr39-17588359251363207">39</a>
</sup></p></section></section><section id="section8-17588359251363207"><h3 class="pmc_sec_title">Hematopoietic stem cell transplantation</h3>
<p>Hematopoietic stem cell transplantation (HSCT) represents a potentially curative therapeutic approach for patients with R/R lymphoma and those presenting with poor prognostic indicators or unfavorable clinical outcomes. It is divided into two types: autologous HSCT (auto-HSCT) and allogeneic HSCT (allo-HSCT). Graft-versus-host disease (GVHD) is a common complication in patients undergoing allo-HSCT. Several studies have shown the changes in gut microbiome in patients undergoing HSCT, characterized by a reduction in gut microbiota diversity and the predominance of specific bacterial taxa.<sup><a href="#bibr39-17588359251363207" class="usa-link" aria-describedby="bibr39-17588359251363207">39</a>,<a href="#bibr40-17588359251363207" class="usa-link" aria-describedby="bibr40-17588359251363207">40</a></sup> Moreover, the level of SCFAs in patients receiving HSCT has been observed a reduction.<sup>
<a href="#bibr41-17588359251363207" class="usa-link" aria-describedby="bibr41-17588359251363207">41</a>
</sup> During the pretreatment phase, antibiotics are administered for intestinal cleansing and as a prophylactic measure. In addition, during the whole process, appropriate antibiotics are utilized based on the patient’s clinical manifestations or bacterial culture results. These comprehensive antimicrobial interventions inevitably exert profound impacts on the gut microbiome. Therefore, analyzing the influence of antibiotic management on HSCT cannot be overlooked.</p>
<section id="section9-17588359251363207"><h4 class="pmc_sec_title">Influence of gut microbiota and its metabolites on HSCT of lymphoma</h4>
<p>First, gut microbiota is associated with side effects. High-dose chemotherapy, commonly utilized as a myeloablative conditioning regimen prior to HSCT, often induces several side effects, such as GI mucositis, which manifests in nausea, vomiting, abdominal pain, and diarrhea. Montassier et al.<sup>
<a href="#bibr42-17588359251363207" class="usa-link" aria-describedby="bibr42-17588359251363207">42</a>
</sup> analyzed gut microbiota composition in patients with non-Hodgkin lymphoma (NHL) who received the same myeloablative conditioning regimen without antibiotic exposure. Post-chemotherapy fecal samples exhibited a significant decrease in phylum <em>Firmicutes</em> abundance and a substantial increase in phylum <em>Proteobacteria</em> abundance. They revealed that the compositional disruption induced by chemotherapy can lead to GI mucositis. Moreover, gut microbiota disruption has been implicated in other critical complications of HSCT, including infections and GVHD. Montassier et al.<sup>
<a href="#bibr43-17588359251363207" class="usa-link" aria-describedby="bibr43-17588359251363207">43</a>
</sup> found that diminished gut microbiota diversity was associated with an elevated risk of bloodstream infections. Butyrate is one of the gut microbiota metabolites. Kaundal et al.<sup>
<a href="#bibr44-17588359251363207" class="usa-link" aria-describedby="bibr44-17588359251363207">44</a>
</sup> observed that persistently low fecal butyrate levels before and after auto-HSCT were associated with a higher risk of post-HSCT carbapenem exposure and antibiotic duration. When it comes to GVHD, Shouval et al.<sup>
<a href="#bibr45-17588359251363207" class="usa-link" aria-describedby="bibr45-17588359251363207">45</a>
</sup> reviewed the impact of conditioning regimens with different intensities on gut microbiota disruption. They found that, compared to non-myeloablative regimens, myeloablative regimens correlated with more severe damage to the gut microbiota, which was associated with a higher risk of GVHD occurrence. Qi et al.<sup>
<a href="#bibr40-17588359251363207" class="usa-link" aria-describedby="bibr40-17588359251363207">40</a>
</sup> observed a lower abundance of genus <em>Roseburia</em> before HSCT conditioning regimens in acute GVHD patients. <em>Roseburia</em> has been shown to produce butyrate. Administration of butyrate has been shown to offer protection against GVHD.<sup>
<a href="#bibr46-17588359251363207" class="usa-link" aria-describedby="bibr46-17588359251363207">46</a>
</sup> Gut microorganisms can metabolize nutrients such as choline, phosphatidylcholine, and carnitine into trimethylamine, which subsequently enters the liver and undergoes enzymatic oxidation to produce trimethylamine N-oxide (TMAO). Wu et al.<sup>
<a href="#bibr47-17588359251363207" class="usa-link" aria-describedby="bibr47-17588359251363207">47</a>
</sup> demonstrated that TMAO can aggravate GVHD, acting as a stimulator in GVHD progression. Furthermore, lower diversity of gut microbiota was linked to inferior OS and PFS in patients undergoing auto-HSCT<sup>
<a href="#bibr39-17588359251363207" class="usa-link" aria-describedby="bibr39-17588359251363207">39</a>
</sup> and higher mortality rates in patients undergoing allo-HSCT.<sup>
<a href="#bibr48-17588359251363207" class="usa-link" aria-describedby="bibr48-17588359251363207">48</a>
</sup> Detailed results are summarized in <a href="#table2-17588359251363207" class="usa-link">Table 2</a>.</p>
<section class="tw xbox font-sm" id="table2-17588359251363207"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Clinical outcomes and gut microbiome in HSCT patients.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">First author</th>
<th align="left" rowspan="1" colspan="1">Disease</th>
<th align="left" rowspan="1" colspan="1">Patients, (<em>n</em>%)</th>
<th align="left" rowspan="1" colspan="1">HSCT regimen</th>
<th align="left" rowspan="1" colspan="1">Clinical outcomes</th>
<th align="left" rowspan="1" colspan="1">Positive microbiota-related factors</th>
<th align="left" rowspan="1" colspan="1">Negative microbiota-related factors</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Montassier et al.<sup>
<a href="#bibr42-17588359251363207" class="usa-link" aria-describedby="bibr42-17588359251363207">42</a>
</sup>
</td>
<td rowspan="1" colspan="1">NHL</td>
<td rowspan="1" colspan="1">28(100)</td>
<td rowspan="1" colspan="1">Myeloablative conditioning regimen</td>
<td rowspan="1" colspan="1">GI mucositis↑</td>
<td rowspan="1" colspan="1">
<em>Firmicutes</em>, <em>Actinobacteria</em>
</td>
<td rowspan="1" colspan="1">
<em>Proteobacteria</em>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Kaundal et al.<sup>
<a href="#bibr44-17588359251363207" class="usa-link" aria-describedby="bibr44-17588359251363207">44</a>
</sup>
</td>
<td rowspan="1" colspan="1">Lymphoma</td>
<td rowspan="1" colspan="1">17(56.7)</td>
<td rowspan="1" colspan="1">Auto-HSCT</td>
<td rowspan="1" colspan="1">Mucositis↑, antibiotic exposure↑</td>
<td rowspan="1" colspan="1">High pre-HSCT fecal butyrate</td>
<td rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Montassier et al.<sup>
<a href="#bibr43-17588359251363207" class="usa-link" aria-describedby="bibr43-17588359251363207">43</a>
</sup>
</td>
<td rowspan="1" colspan="1">NHL</td>
<td rowspan="1" colspan="1">28(100)</td>
<td rowspan="1" colspan="1">Myeloablative conditioning regimen</td>
<td rowspan="1" colspan="1">Bloodstream infections↑</td>
<td rowspan="1" colspan="1">High overall diversity, <em>Barnesiellaceae</em>, <em>Faecalibacterium</em>
</td>
<td rowspan="1" colspan="1">
<em>Erysipelotrichaceae</em>, <em>Veillonella</em>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Qi et al.<sup>
<a href="#bibr40-17588359251363207" class="usa-link" aria-describedby="bibr40-17588359251363207">40</a>
</sup>
</td>
<td rowspan="1" colspan="1">Lymphoma</td>
<td rowspan="1" colspan="1">1(1.6)</td>
<td rowspan="1" colspan="1">Allo-HSCT</td>
<td rowspan="1" colspan="1">Acute GVHD↑</td>
<td rowspan="1" colspan="1">
<em>Roseburia</em>, <em>Streptococcaceae</em>, <em>Streptococcus</em>, <em>Rothia mucilaginosa</em>
</td>
<td rowspan="1" colspan="1">
<em>Acinetobacter johnsonii</em>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hayase et al.<sup>
<a href="#bibr50-17588359251363207" class="usa-link" aria-describedby="bibr50-17588359251363207">50</a>
</sup>
</td>
<td rowspan="1" colspan="1">Acute GVHD</td>
<td rowspan="1" colspan="1">37(100)</td>
<td rowspan="1" colspan="1">Allo-HSCT</td>
<td rowspan="1" colspan="1">aGI-GVHD↑, treatment responsiveness of GVHD↓</td>
<td rowspan="1" colspan="1">
<em>Bacteroides ovatus</em>
</td>
<td rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Shouval et al.<sup>
<a href="#bibr45-17588359251363207" class="usa-link" aria-describedby="bibr45-17588359251363207">45</a>
</sup>
</td>
<td rowspan="1" colspan="1">Lymphoma/CLL</td>
<td rowspan="1" colspan="1">231(19.4)</td>
<td rowspan="1" colspan="1">Allo-HSCT</td>
<td rowspan="1" colspan="1">GVHD risk↑</td>
<td rowspan="1" colspan="1">High diversity (non-myeloablative regimens related)</td>
<td rowspan="1" colspan="1">Low diversity (myeloablative regimens related)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Khan et al.<sup>
<a href="#bibr39-17588359251363207" class="usa-link" aria-describedby="bibr39-17588359251363207">39</a>
</sup>
</td>
<td rowspan="1" colspan="1">Lymphoma</td>
<td rowspan="1" colspan="1">227(42.5)</td>
<td rowspan="1" colspan="1">Auto-HSCT</td>
<td rowspan="1" colspan="1">OS↓, PFS↓</td>
<td rowspan="1" colspan="1">High diversity</td>
<td rowspan="1" colspan="1">
<em>Enterococcus</em>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Peled et al.<sup>
<a href="#bibr48-17588359251363207" class="usa-link" aria-describedby="bibr48-17588359251363207">48</a>
</sup>
</td>
<td rowspan="1" colspan="1">NHLHL</td>
<td rowspan="1" colspan="1">229(17)31(2)</td>
<td rowspan="1" colspan="1">Allo-HSCT</td>
<td rowspan="1" colspan="1">OS↓, GVHD-Related Mortality↑, Transplantation-Related Mortality↑</td>
<td rowspan="1" colspan="1">High pre-/peri-engraftment diversity</td>
<td rowspan="1" colspan="1">Low diversity, domination by single taxa (<em>Enterococcus</em>, <em>Streptococcus</em>) after HSCT</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table2-17588359251363207/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn2-17588359251363207"><p>aGI-GVHD, acute gastrointestinal graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; CLL, chronic lymphocytic leukemia; GI, gastrointestinal; GVHD, graft-versus-host disease; HL, Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; NHL, non-Hodgkin lymphoma; OS, overall survival; PFS, progression-free survival.</p></div></div></section></section><section id="section10-17588359251363207"><h4 class="pmc_sec_title">Influence of antibiotic management on HSCT of lymphoma</h4>
<p>Infection and GVHD are two major complications associated with HSCT, with antibiotic management strategies playing a critical role in their development and progression. Weber et al.<sup>
<a href="#bibr49-17588359251363207" class="usa-link" aria-describedby="bibr49-17588359251363207">49</a>
</sup> suggested “restrictive antibiotic strategy” in HSCT. In their findings, this strategy can preserve the diversity of gut microbiota and potentially beneficial taxa without increasing the risk of bacterial sepsis or documented infections. Notably, this approach also demonstrated a reduction in the incidence of severe acute GI GVHD (aGI-GVHD), a life-threatening complication of allo-HSCT that remained a leading cause of transplantation-related mortality due to its challenging treatment. Hayase et al.<sup>
<a href="#bibr50-17588359251363207" class="usa-link" aria-describedby="bibr50-17588359251363207">50</a>
</sup> further demonstrated that microbiome dysbiosis induced by carbapenem antibiotics was correlated with the exacerbation of aGI-GVHD and impaired treatment responsiveness. They also showed that carbapenem use was associated with a reduction in <em>Bacteroides ovatus</em>, which, by metabolizing dietary polysaccharides into monosaccharides, restricts <em>Bacteroides thetaiotaomicron</em>’s mucolytic activity, thereby preserving intestinal mucus integrity. Longer duration of treatment with meropenem and piperacillin-tazobactam was linked to an increase in the detection of genus <em>Staphylococcus</em> following allo-HSCT, including two potentially pathogenic species, <em>Staphylococcus epidermidis</em> and <em>Staphylococcus aureus</em>, which may elevate the risk of bacteremia in these patients.<sup>
<a href="#bibr41-17588359251363207" class="usa-link" aria-describedby="bibr41-17588359251363207">41</a>
</sup> Further, a prospective, multicenter, observational study (ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT03727113" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03727113</a>) focusing on microbiome modulation during HSCT has been carried out. This study was designed to investigate whether a more cautious approach to antibiotic use during HSCT can better preserve the composition and diversity of gut microbiota, thereby reducing severe post-transplant complications. This study may provide stronger evidence supporting the role of gut microbiota modulation in HSCT, though no relevant literature has been published to date, and further research needs to be carried out. Therefore, understanding the impact of gut microbiota on HSCT and the optimal use of antibiotics may decrease the incidence of HSCT complications and benefit patients who undergo HSCT.</p></section></section><section id="section11-17588359251363207"><h3 class="pmc_sec_title">Target therapy</h3>
<section id="section12-17588359251363207"><h4 class="pmc_sec_title">Immune checkpoint inhibitors</h4>
<p>The evasion of immune surveillance is a primary mechanism that cancer cells utilize for survival and proliferation. The application of immune checkpoint inhibitors (ICIs), especially monoclonal antibodies targeting programmed cell death receptor-1 (PD-1), has shown good efficacy. However, their clinical application is often limited by the fact that more than half of the patients experience disease progression or a loss of therapeutic response over time. The gut microbiome plays an important role in regulating systemic immune responses. Therefore, understanding the interaction between the gut microbiome and ICIs could provide valuable insights to optimize ICI therapy. However, current evidence remains limited, particularly in lymphoma, highlighting the need for further exploration.</p>
<section id="section13-17588359251363207"><h5 class="pmc_sec_title">Influence of gut microbiota on ICIs of lymphoma</h5>
<p>The efficacy of ICIs may be associated with gut microbiota. Casadei et al.<sup>
<a href="#bibr51-17588359251363207" class="usa-link" aria-describedby="bibr51-17588359251363207">51</a>
</sup> showed that patients who responded to anti-PD-1 therapy (nivolumab or pembrolizumab) had a notable increase in the abundance of genus <em>Lachnospira</em>. In contrast, in non-responding patients, the abundance of family <em>Enterobacteriaceae</em> increased. As we already know, <em>Lachnospiraceae</em> can produce SCFAs, mainly butyrate. Butyrate exerts immunomodulatory effects, enhancing antitumor immunity by modulating immune cell populations, including macrophages, dendritic cells, regulatory T cells, T helper cells, and plasma cells.</p></section><section id="section14-17588359251363207"><h5 class="pmc_sec_title">Influence of antibiotic management on ICIs of lymphoma</h5>
<p>Previous research has indicated that the administration of antibiotics may reduce the effectiveness of ICIs in managing solid tumors. A study revealed that antibiotic use within 90 days prior to initiating ICIs therapy in patients with classical HL was associated with worse median OS and PFS.<sup>
<a href="#bibr52-17588359251363207" class="usa-link" aria-describedby="bibr52-17588359251363207">52</a>
</sup> However, larger prospective studies are needed to validate these findings and explore optimal timing windows.</p></section></section><section id="section15-17588359251363207"><h4 class="pmc_sec_title">Epigenetic modifications</h4>
<p>Epigenetic modifications play a crucial role in modulating hematological tumor cells.<sup>
<a href="#bibr53-17588359251363207" class="usa-link" aria-describedby="bibr53-17588359251363207">53</a>
</sup> Epigenetic modifications enable cells to change gene expression without changing the deoxyribonucleic acid (DNA) sequence, thus causing changes in gene phenotype. Given the reversibility of epigenetic alterations, they emerge as promising therapeutic targets in the field of cancer treatment.<sup>
<a href="#bibr54-17588359251363207" class="usa-link" aria-describedby="bibr54-17588359251363207">54</a>
</sup> Epigenetic regulation includes histone modification, DNA methylation, non-coding Ribonucleic Acid effect, and chromatin recombination. Abnormal hypermethylation and deacetylation leading to the silencing of tumor suppressor genes are crucial regulatory points contributing to chemoresistance in DLBCL.<sup><a href="#bibr55-17588359251363207" class="usa-link" aria-describedby="bibr55-17588359251363207">55</a>,<a href="#bibr56-17588359251363207" class="usa-link" aria-describedby="bibr56-17588359251363207">56</a></sup> DNA methyltransferase (DNMT) and HDAC are two key enzymes in epigenetic modification. Inhibiting DNMT or HDAC can promote demethylation and acetylation of tumor suppressor genes, thereby inhibiting tumor growth.<sup><a href="#bibr57-17588359251363207" class="usa-link" aria-describedby="bibr57-17588359251363207">57</a>,<a href="#bibr58-17588359251363207" class="usa-link" aria-describedby="bibr58-17588359251363207">58</a></sup> Pera et al.<sup>
<a href="#bibr59-17588359251363207" class="usa-link" aria-describedby="bibr59-17588359251363207">59</a>
</sup>’s research indicated that combining inhibitors of DNMT and HDAC may offer a delayed but promising chemosensitization effect. This represents a therapeutic strategy to overcome chemoresistance in DLBCL.<sup>
<a href="#bibr55-17588359251363207" class="usa-link" aria-describedby="bibr55-17588359251363207">55</a>
</sup> Our previous study<sup>
<a href="#bibr60-17588359251363207" class="usa-link" aria-describedby="bibr60-17588359251363207">60</a>
</sup> further confirmed the promising effect of a dual epigenetic agent-primed immunochemotherapy regimen, CD-R-GemOx (comprising chidamide, decitabine, rituximab, gemcitabine, and oxaliplatin), in R/R DLBCL patients who had failed salvage treatment. The composition of the human microbiota is very complex, mainly including bacteria, archaea, fungi, viruses, and some tiny protists. The genome of the microbiota is 150 times larger than the human genome, which is named the second human genome. It plays a crucial role in regulating human metabolic processes and is a potentially influential environmental element that may shape our epigenome. Significantly, unlike the immutable genomic composition, the gut microbiome is alterable, making it a promising target for therapeutic interventions. Therefore, epigenetic regulation is increasingly regarded as an effective mechanism for the microbiome to affect host physiology.</p>
<section id="section16-17588359251363207"><h5 class="pmc_sec_title">Influence of gut microbiota and its metabolites on epigenetic modifications of lymphoma</h5>
<p>It has been reported that microbiota-derived metabolites can regulate epigenetic modifications. SCFAs, such as butyrate produced by genera <em>Butyricimonas</em>, <em>Faecalibacterium</em>, <em>Lachnospira</em>, and <em>Ruminococcus</em>, can traverse the boundary of the intestinal epithelium and exert gene expression and epigenetic modulation within the host, including DNA methylation and histone modification.<sup>
<a href="#bibr61-17588359251363207" class="usa-link" aria-describedby="bibr61-17588359251363207">61</a>
</sup> A previous study revealed that butyrate derived from a high-fiber diet enhances histone acetylation and pro-apoptotic gene expression, inhibiting lymphoma cell proliferation and inducing apoptosis.<sup>
<a href="#bibr62-17588359251363207" class="usa-link" aria-describedby="bibr62-17588359251363207">62</a>
</sup> Further, the decreased abundance of butyrate-producing bacteria was related to an increased risk of lymphoma progression and a poorer treatment response.<sup><a href="#bibr51-17588359251363207" class="usa-link" aria-describedby="bibr51-17588359251363207">51</a>,<a href="#bibr63-17588359251363207" class="usa-link" aria-describedby="bibr63-17588359251363207">63</a>,<a href="#bibr64-17588359251363207" class="usa-link" aria-describedby="bibr64-17588359251363207">64</a></sup> Indole-based metabolites, such as indole-3-propionic acid, which were produced by <em>Lactobacillus johnsonii</em> and <em>Clostridium sporogenes</em> through metabolizing tryptophan, an essential amino acid from protein-rich food, were also reported to be capable of changing immune cell stemness, enhancing the efficacy of anti-PD-1 immunotherapy against lymphoma cells through modulating HDAC processes.<sup>
<a href="#bibr65-17588359251363207" class="usa-link" aria-describedby="bibr65-17588359251363207">65</a>
</sup> However, there is limited understanding regarding the precise function of the interaction between microbial indole metabolites and the epigenetic mechanisms of the host.<sup>
<a href="#bibr66-17588359251363207" class="usa-link" aria-describedby="bibr66-17588359251363207">66</a>
</sup> Together, these findings underscore the importance of gut microbiota and its metabolites in lymphoma biology and suggest potential novel therapeutic strategies targeting the microbiota-epigenome axis.</p></section><section id="section17-17588359251363207"><h5 class="pmc_sec_title">Preliminary evidence on antibiotic-modulated epigenetics in lymphoma</h5>
<p>Limited data are currently available about the function of antibiotic management in epigenetic modifications in lymphoma have been published in the literature. Ragheb et al.<sup>
<a href="#bibr67-17588359251363207" class="usa-link" aria-describedby="bibr67-17588359251363207">67</a>
</sup> found that HDAC inhibitor vorinostat and anticancer antibiotic Mithramycin in combination showed clear synergy or potentiation in patient-derived Sézary syndrome (SS) cells apoptosis as well as epigenetic modifications. Mithramycin broadly affects epigenetic modifications by directly inhibiting Sp1 binding to DNA, binding to histones, and indirectly influencing gene expression through the inhibition of DNMT1 and other histone-modifying enzymes, thereby altering histone acetylation and methylation. The combination of vorinostat and Mithramycin appears to induce changes in histone acetylation, methylation, and other epigenetic marks, leading to a greater impact on gene expression and cell death. This data provided preliminary clues on the individual and combined effects of HDAC inhibitor and antibiotic Mithramycin in SS cells and highlighted a potential therapeutic interest of this novel pair of drugs for the treatment of SS patients. However, the research on the interaction between antibiotic management, epigenetics, and lymphoma is limited currently. As a result, there is a need for further investigation to elucidate these complex interactions.</p></section></section><section id="section18-17588359251363207"><h4 class="pmc_sec_title">Chimeric antigen receptor T-cell therapy</h4>
<p>Lymphocytes isolated from peripheral blood are genetically modified by incorporating a chimeric antigen receptor (CAR) using a replication-deficient viral vector.<sup>
<a href="#bibr68-17588359251363207" class="usa-link" aria-describedby="bibr68-17588359251363207">68</a>
</sup> Following this modification, these lymphocytes are reintroduced into the patient’s system, enabling them to target and destroy lymphoma cells identified by their T-cell receptors (TCRs).<sup>
<a href="#bibr68-17588359251363207" class="usa-link" aria-describedby="bibr68-17588359251363207">68</a>
</sup> CAR-T cell (CAR-T) therapy has been incorporated into the National Comprehensive Cancer Network guidelines as a recommended second-line treatment for patients with relapsed disease (&lt;12 months) or primary refractory DLBCL, reflecting its substantial therapeutic potential, which has indeed been demonstrated through clinical evidence. However, although the response rate of CAR-T ranges from 40% to 90% in patients with R/R large B-cell lymphoma, only about 30%–40% of patients can achieve durable remission.<sup><a href="#bibr69-17588359251363207" class="usa-link" aria-describedby="bibr69-17588359251363207">69</a>,<a href="#bibr70-17588359251363207" class="usa-link" aria-describedby="bibr70-17588359251363207">70</a></sup> Immune-related toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS), represent pivotal contributors to the mortality rates in CAR-T therapy.<sup><a href="#bibr71-17588359251363207" class="usa-link" aria-describedby="bibr71-17588359251363207">71</a>,<a href="#bibr72-17588359251363207" class="usa-link" aria-describedby="bibr72-17588359251363207">72</a></sup> In general, CAR-T therapy indeed demonstrates significant therapeutic potential. However, some patients do not respond to it, and some others experience severe adverse reactions, indicating the need for personalized optimization of the treatment. The role of the gut microbiome in cancer treatment has been established, and increasing evidence suggests that the characteristics of the gut microbiome can be used to predict treatment response or adverse reactions.<sup>
<a href="#bibr73-17588359251363207" class="usa-link" aria-describedby="bibr73-17588359251363207">73</a>
</sup> Targeting the gut microbiome to enhance the antilymphoma efficacy and attenuate CAR-T therapy’s toxicity may be a new approach.</p>
<section id="section19-17588359251363207"><h5 class="pmc_sec_title">Influence of gut microbiota and its metabolites on CAR-T therapy of lymphoma</h5>
<p>Multiple studies have shown that the composition of the gut microbiome relates to the efficacy and toxicity of CAR-T therapy. Smith et al.<sup>
<a href="#bibr64-17588359251363207" class="usa-link" aria-describedby="bibr64-17588359251363207">64</a>
</sup> found that a higher abundance of genera <em>Ruminococcus</em>, <em>Faecalibacterium</em>, and <em>Bacteroides</em> was associated with the response to CD19 CAR-T therapy, and <em>Bacteroides</em> abundance may serve as a biomarker for predicting toxicity, with a higher abundance potentially associated with a higher risk of toxicity. However, the study did not exclude patients who may have previously been exposed to antibiotics, a factor that could potentially interfere with the final conclusion. Focusing on a non-antibiotic-disrupted gut microbiome, Stein-Thoeringer et al.<sup>
<a href="#bibr74-17588359251363207" class="usa-link" aria-describedby="bibr74-17588359251363207">74</a>
</sup> identified <em>Bacteroides</em>, <em>Ruminococcus</em>, <em>Eubacterium</em>, and <em>Akkermansia</em> as the primary taxa that can influence the predictive outcome of CAR-T therapy response. They found that a high abundance of <em>Akkermansia muciniphila</em> was associated with higher levels of peripheral T cells, predicting the possibility of producing better quality CAR-T. It is known that <em>A. muciniphila</em> possesses the ability to produce SCFAs such as acetate and propionate, and <em>F. prausnitzii</em> to produce butyrate. SCFAs can enhance genetically engineered T cells by imparting more stable TCR/CAR transgene expression, optimal functionality, memory potential, and improved therapeutic activity in vivo. Recognizing their pleiotropic effects in vivo, Rangan and Mondino<sup>
<a href="#bibr75-17588359251363207" class="usa-link" aria-describedby="bibr75-17588359251363207">75</a>
</sup> advocated for the use of SCFAs in T-cell manufacturing. Building on this, Prasad et al.<sup>
<a href="#bibr76-17588359251363207" class="usa-link" aria-describedby="bibr76-17588359251363207">76</a>
</sup> proposed an approach for boosting CAR-T effectiveness by increasing the levels of SCFAs during the ex vivo production process of CAR-T. Then they discovered an enhanced CAR-T cytotoxicity and cytokine secretion in prolonged serial killing assays with repeated tumor cell exposures and elevated SCFAs. However, research on gut microbial metabolites, including SCFAs, has been limited to preclinical studies and has not yet been carried out in clinical and real-world studies.</p></section><section id="section20-17588359251363207"><h5 class="pmc_sec_title">Influence of antibiotic management on CAR-T therapy of lymphoma</h5>
<p>Antibiotic management may damage or facilitate CAR-T therapy. A dual-center study<sup>
<a href="#bibr64-17588359251363207" class="usa-link" aria-describedby="bibr64-17588359251363207">64</a>
</sup> found that patients with NHL who received piperacillin/tazobactam, meropenem, and imipenem/cilastatin (broad-spectrum antibiotics) within 4 weeks before CD19 CAR-T therapy exhibited poorer survival outcomes, including OS and PFS. To further investigate these findings, the research team employed A20 tumor-bearing mice to investigate the effect of oral vancomycin, primarily targeting gram-positive bacteria, on CAR-T therapy. Their findings revealed that oral vancomycin administration could enhance the tumor elimination mediated by CAR-T, whereas oral neomycin and metronidazole, which mainly target gram-negative bacteria, failed to exhibit such an effect.<sup>
<a href="#bibr77-17588359251363207" class="usa-link" aria-describedby="bibr77-17588359251363207">77</a>
</sup> Moreover, another multicenter study<sup>
<a href="#bibr74-17588359251363207" class="usa-link" aria-describedby="bibr74-17588359251363207">74</a>
</sup> also revealed that broad-spectrum antibiotics were associated with a worse PFS and OS. The correlation between antibiotic management and the efficacy of CAR-T therapy may be due to a poorer disease state or higher inflammation levels prior to antibiotic exposure, or alternatively, by gut microbiome disruption induced by antibiotic exposure. Recently, data from a single-center cohort<sup>
<a href="#bibr76-17588359251363207" class="usa-link" aria-describedby="bibr76-17588359251363207">76</a>
</sup> further revealed some correlations between antibiotic management, the disruption of metabolome and CAR-T therapy. Patients treated with broad-spectrum antibiotics, particularly those with anaerobic coverage, showed worse survival outcomes after CAR-T therapy and notable changes in their gut and serum metabolic profiles, such as depletion of SCFAs. When it comes to the correlation between antibiotic management and CAR-T-mediated toxicities, Smith et al.<sup>
<a href="#bibr64-17588359251363207" class="usa-link" aria-describedby="bibr64-17588359251363207">64</a>
</sup> found that exposure to broad-spectrum antibiotics in the CAR-T pre-infusion time window raised the rate of ICANS. This finding aligned with the potential link between the gut microbiota and ICANS via the gut-brain axis.<sup><a href="#bibr78-17588359251363207" class="usa-link" aria-describedby="bibr78-17588359251363207">78</a>,<a href="#bibr79-17588359251363207" class="usa-link" aria-describedby="bibr79-17588359251363207">79</a></sup> However, data showed no significant correlation between antibiotics and CRS. Based on current studies, prudent use of broad-spectrum antibiotics appears advisable for CAR-T therapy. Detailed results are summarized in <a href="#table3-17588359251363207" class="usa-link">Table 3</a>.</p>
<section class="tw xbox font-sm" id="table3-17588359251363207"><h6 class="obj_head">Table 3.</h6>
<div class="caption p"><p>Clinical efficacy and gut microbiome in CAR-T-treated patients.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">First author</th>
<th align="left" rowspan="1" colspan="1">CAR-T products</th>
<th align="left" rowspan="1" colspan="1">Disease</th>
<th align="left" rowspan="1" colspan="1">Patient,<br><em>n</em> (%)</th>
<th align="left" rowspan="1" colspan="1">antibiotic exposure,<br><em>n</em> (%)</th>
<th align="left" rowspan="1" colspan="1">PFS</th>
<th align="left" rowspan="1" colspan="1">OS</th>
<th align="left" rowspan="1" colspan="1">CRS</th>
<th align="left" rowspan="1" colspan="1">ICANS</th>
<th align="left" rowspan="1" colspan="1">Positive microbiota-related factors</th>
<th align="left" rowspan="1" colspan="1">Negative microbiota-related factors</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Smith et al.<sup>
<a href="#bibr64-17588359251363207" class="usa-link" aria-describedby="bibr64-17588359251363207">64</a>
</sup>
</td>
<td rowspan="1" colspan="1">CD19 CAR-T</td>
<td rowspan="1" colspan="1">NHL</td>
<td rowspan="1" colspan="1">137 (100)</td>
<td rowspan="1" colspan="1">No, 56 (36.4)</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">
<em>Ruminococcus</em>, <em>Bacteroides</em>,<br><em>Faecalibacterium</em>
</td>
<td rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Any, 81 (63.6)</td>
<td rowspan="1" colspan="1">HR 1.29 (<em>p</em> = 0.256)</td>
<td rowspan="1" colspan="1">HR 2.54 (<em>p</em> = 0.001)</td>
<td rowspan="1" colspan="1">
<em>p</em> = 0.179</td>
<td rowspan="1" colspan="1">
<em>p</em> = 0.003</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">P-I-M, 21 (20.6)</td>
<td rowspan="1" colspan="1">HR 1.83 (<em>p</em> = 0.038)</td>
<td rowspan="1" colspan="1">HR 3.37 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">
<em>p</em> = 0.154</td>
<td rowspan="1" colspan="1">
<em>p</em> &lt; 0.001</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Stein-Thoeringer et al.<sup>
<a href="#bibr74-17588359251363207" class="usa-link" aria-describedby="bibr74-17588359251363207">74</a>
</sup>
</td>
<td rowspan="1" colspan="1">CD19 CAR-T</td>
<td rowspan="1" colspan="1">NHL</td>
<td rowspan="1" colspan="1">172 (100)</td>
<td rowspan="1" colspan="1">No, 110 (64.0)</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">
<em>Roseburia</em>, <em>Bifidobacterium</em>, <em>Lactobacillus</em> and <em>Eubacterium</em> spp.</td>
<td rowspan="1" colspan="1">Reduced alpha-diversity, <em>Prevotella</em>, <em>Veillonella</em>, <em>Enterococcus</em> spp.</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Any, 62 (36.0)</td>
<td rowspan="1" colspan="1">HR 2.04 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">HR 2.39 (<em>p</em> = 0.003)</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">High-risk antibiotic<sup>
<a href="#table-fn3-17588359251363207" class="usa-link">a</a>
</sup>, 36 (20.9)</td>
<td rowspan="1" colspan="1">HR 3.05 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">HR 2.99 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">
<em>p</em> = 0.085</td>
<td rowspan="1" colspan="1">
<em>p</em> = 0.039</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Prasad et al.<sup>
<a href="#bibr76-17588359251363207" class="usa-link" aria-describedby="bibr76-17588359251363207">76</a>
</sup>
</td>
<td rowspan="1" colspan="1">CD19 CAR-T</td>
<td rowspan="1" colspan="1">DLBCL</td>
<td rowspan="1" colspan="1">422 (100)</td>
<td rowspan="1" colspan="1">No, 251(59.5)</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">SCFAs (acetic acid, butyric acid, isovaleric acid, propionic acid, valeric acid), TMAO, indoxyl sulfate, cresyl sulfate, ursodeoxycholate</td>
<td rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Any, 171(40.5)</td>
<td rowspan="1" colspan="1">HR 1.71 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">HR 2.38 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">CEF, 66(15.6)</td>
<td rowspan="1" colspan="1">HR 1.34 (<em>p</em> = 0.090)</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">ANA, 64(15.2)</td>
<td rowspan="1" colspan="1">HR 2.39 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">P-I-M, 35(8.3)</td>
<td rowspan="1" colspan="1">HR 3.12 (<em>p</em> &lt; 0.001)</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table3-17588359251363207/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="table-fn3-17588359251363207">
<sup>a</sup><p class="display-inline">High-risk antibiotic: piperacillin/tazobactam, meropenem, cefepime, ceftazidime.</p>
</div>
<div class="fn" id="table-fn4-17588359251363207"><p>ANA, target anaerobic commensals; CAR-T, chimeric antigen receptor T-cell therapy; CEF, anti-pseudomonal cephalosporins; CRS, cytokine-releasing syndrome; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; ICANS, immune effector cell-associated neurotoxicity syndrome; NHL, non-Hodgkin lymphoma; OS, overall survival; PFS, progression-free survival; P-I-M, piperacillin/tazobactam, imipenem, meropenem; SCFAs, short-chain fatty acids; TMAO, trimethylamine N-oxide.</p></div>
</div></section><p>Specific gut microbial taxa and their metabolites differentially influence treatment responses across lymphoma subtypes through immune modulation, epigenetic regulation, and ecological competition. Summarized in <a href="#table4-17588359251363207" class="usa-link">Table 4</a>.</p>
<section class="tw xbox font-sm" id="table4-17588359251363207"><h6 class="obj_head">Table 4.</h6>
<div class="caption p"><p>Clinical associations and mechanistic roles of gut microbiota in lymphoma therapeutics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
<col align="char" char="." span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Gut microbiota</th>
<th align="left" rowspan="1" colspan="1">Therapeutic context</th>
<th align="left" rowspan="1" colspan="1">Clinical association</th>
<th align="left" rowspan="1" colspan="1">Key metabolites</th>
<th align="left" rowspan="1" colspan="1">Potential mechanisms</th>
<th align="left" rowspan="1" colspan="1">Reference</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">
<em>Enterobacteriaceae</em>
</td>
<td rowspan="1" colspan="1">DLBCL chemotherapy</td>
<td rowspan="1" colspan="1">↑ in patients vs controls</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">Opportunistic pathogenicity; inflammatory modulation; ecological competition with beneficial commensal bacteria</td>
<td rowspan="1" colspan="1">18</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">↑ abundance → worse outcome/febrile neutropenia post-R-CHOP</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Alistipes</em>
</td>
<td rowspan="1" colspan="1">DLBCL chemotherapy</td>
<td rowspan="1" colspan="1">↑ abundance → poorer response</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">Uncharacterized; protective effects in MR studies, bidirectional interaction</td>
<td rowspan="1" colspan="1">28, 34</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Veillonellaceae</em>
</td>
<td rowspan="1" colspan="1">DLBCL Chemotherapy</td>
<td rowspan="1" colspan="1">↑ abundance → ↓ NCR risk</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">Uncharacterized, probably through immune regulation</td>
<td rowspan="1" colspan="1">34</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Lactobacillus fermentum</em>
</td>
<td rowspan="1" colspan="1">DLBCL chemotherapy</td>
<td rowspan="1" colspan="1">Emergence → better outcome</td>
<td rowspan="1" colspan="1">–</td>
<td rowspan="1" colspan="1">EPS/polysaccharide biosynthesis potential</td>
<td rowspan="1" colspan="1">34</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Parabacteroides distasonis</em>
</td>
<td rowspan="1" colspan="1">PCNSL Chemotherapy (HD-MTX)</td>
<td rowspan="1" colspan="1">↑ abundance (⩾Percentile66) → ↑ PFS/OS</td>
<td rowspan="1" colspan="1">Betaine–valine</td>
<td rowspan="1" colspan="1">Gut-brain axis: betaine–valine → ↑ CD8+ T-cell infiltration in CSF/tumor</td>
<td rowspan="1" colspan="1">35</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Roseburia</em>
</td>
<td rowspan="1" colspan="1">HSCT (acute GVHD prevention)</td>
<td rowspan="1" colspan="1">↓ in aGVHD patients pre-HSCT</td>
<td rowspan="1" colspan="1">Butyrate</td>
<td rowspan="1" colspan="1">Uncharacterized, probably through butyrate</td>
<td rowspan="1" colspan="1">40</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Lachnospiraceae</em>
</td>
<td rowspan="1" colspan="1">B-cell Lymphoma ICIs</td>
<td rowspan="1" colspan="1">↑ abundance → ↑ ORR</td>
<td rowspan="1" colspan="1">Butyrate</td>
<td rowspan="1" colspan="1">Uncharacterized, probably through butyrate</td>
<td rowspan="1" colspan="1">51</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Akkermansia muciniphila</em>
</td>
<td rowspan="1" colspan="1">CAR-T therapy</td>
<td rowspan="1" colspan="1">Predicts CAR-T response (pre-infusion T-cell levels)</td>
<td rowspan="1" colspan="1">Acetate/propionate</td>
<td rowspan="1" colspan="1">SCFA → enhanced T-cell effector cytokines</td>
<td rowspan="1" colspan="1">74</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>Faecalibacterium prausnitzii</em>
</td>
<td rowspan="1" colspan="1">NKTCL treatment</td>
<td rowspan="1" colspan="1">↓ abundance in patients</td>
<td rowspan="1" colspan="1">Butyrate</td>
<td rowspan="1" colspan="1">Butyrate → ↑ histone acetylation at SOCS1 promoter → JAK-STAT suppression</td>
<td rowspan="1" colspan="1">84</td>
</tr>
<tr>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1">Correlates with ↓ PFS/OS</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/table4-17588359251363207/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="table-fn5-17588359251363207"><p>aGVHD, acute graft-versus-host disease; CAR-T, chimeric antigen receptor T-cell therapy; CSF, cerebrospinal fluid; DLBCL, diffuse large B-cell lymphoma; EPS, exopolysaccharide; GVHD, graft-versus-host disease; HD-MTX, high-dose methotrexate; HSCT, hematopoietic stem cell transplantation; ICIs, immune checkpoint inhibitors; JAK-STAT, Janus kinase-signal transducer and activator of transcription; MR, Mendelian Randomization; NCR, non-complete response; NKTCL, natural killer/T-cell lymphoma; ORR, objective response rate; OS, overall survival; PCNSL, primary central nervous system lymphoma; PFS, progression-free survival; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; SCFA, short-chain fatty acids; SOCS1, suppressor of cytokine signaling 1.</p></div></div></section></section></section></section></section><section id="section21-17588359251363207"><h2 class="pmc_sec_title">Limitations and future</h2>
<section id="section22-17588359251363207"><h3 class="pmc_sec_title">Limitations in gut microbiome research for lymphoma</h3>
<p>First, the use of fecal samples to estimate the gut microbiome presents inherent limitations. While fecal samples are widely used due to their accessibility and the ability to obtain sufficient sample sizes, they provide only a partial representation of the gut microbiome. Fecal microbiome analysis does not accurately reflect the composition of the mucosal microbiome in different regions of the GI tract, nor does it fully capture the luminal microbiome, which can differ significantly from the fecal microbiome.<sup>
<a href="#bibr80-17588359251363207" class="usa-link" aria-describedby="bibr80-17588359251363207">80</a>
</sup> Feces are often far from the GI tract that we investigate and are always stored in the rectum, where they undergo active dehydration and ferment bacteria that are not common in other parts of the lumen. In addition, the distribution of fecal microflora in feces is uneven, which is a spatially organized multicellular community.<sup>
<a href="#bibr81-17588359251363207" class="usa-link" aria-describedby="bibr81-17588359251363207">81</a>
</sup> Consequently, there is a need to find a more representative sample to better reflect the composition of gut microbiota. Second, research between gut microbiome and lymphoma remains limited, and the majority of studies have been conducted with a relatively small sample size, which may not adequately represent the broader population, leading to potential biases and increased uncertainty in the findings. Numerous observational studies have already confirmed that lymphoma patients possess distinct gut microbiota compared to healthy individuals, which is associated with disease stage, treatment responsiveness, and adverse reactions. Several clinical trials are now in the recruiting phase to confirm the relationship between gut microbiota and lymphoma. <a href="https://clinicaltrials.gov/ct2/show/NCT05725720" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05725720</a> is a clinical study focusing on the characteristics of gut microbiota during CAR-T therapy to demonstrate its role in treatment prognosis. A clinical trial, <a href="https://clinicaltrials.gov/ct2/show/NCT06218602" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT06218602</a>, aims to evaluate whether the addition of Fecal Microbiota Transplantation (FMT) can improve the gut microbiota disrupted by antibiotics, and its impact on therapeutic efficacy and prognosis. However, up to now, no prospective study specifically designed for lymphoma has been published to address these gaps. Therefore, larger, prospective clinical trials should be conducted to provide a more comprehensive understanding of the complex interactions between the gut microbiome and lymphoma. Third, the gut microbiome is a complex and dynamic ecosystem, influenced by a multitude of factors such as diet and antibiotics. Given its complexity, it is paramount to rigorously control for confounding variables in research to ensure the accuracy and reliability of findings. Moreover, it is necessary to design personalized treatment plans due to the individual differences in gut microbiome composition. We can potentially enhance therapeutic outcomes and minimize adverse effects by tailoring treatment strategies to each patient’s unique microbial profile and clinical presentation. Fourth, the underlying mechanisms by which the gut microbiome influences lymphoma require further investigation.</p></section><section id="section23-17588359251363207"><h3 class="pmc_sec_title">Further direction of microbiome therapy in lymphoma</h3>
<p>The gut microbiome influences the response to lymphoma therapy via immune and epigenetic mechanisms. A critical condition for the gut microbiome to exert its function is homeostasis. Multiple strategies for microbiome therapy are available and are widely employed to restore gut microbiome homeostasis. Utilizing specific microorganisms or their metabolites as therapeutic agents, such as targeted treatments including special diets, prebiotics and probiotics, FMT, and butyrate supplementation, has demonstrated significant potential in reducing treatment-related complications and enhancing outcomes for patients with hematologic malignancies (<a href="#fig1-17588359251363207" class="usa-link">Figure 1</a>). We suggest these interventions should be primarily used as adjuncts. Combining microbiome interventions with standard lymphoma regimens can potentially improve treatment efficacy.</p>
<figure class="fig xbox font-sm" id="fig1-17588359251363207" title="This diagram illustrates various strategies and mechanisms for improving lymphoma treatment through microbiome therapy within the human body. It highlights the role of gut microbiota-targeted interventions, such as the use of probiotics and prebiotics, a high-fiber diet, butyrate supplementation, protein consumption, and fecal microbiota transplantation, in modulating the immune system and tumor microenvironment. The diagram also explores the potential of antibiotics to disrupt microbiota balance and the impact of these interventions on immune and epigenetic pathways, ultimately promoting the differentiation of T cells and enhancing antilymphoma responses, while suppressing lymphoma cell proliferation and promoting apoptosis."><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12365434_10.1177_17588359251363207-fig1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/080b/12365434/5af527631b0a/10.1177_17588359251363207-fig1.jpg" loading="lazy" height="631" width="724" alt="This diagram illustrates various strategies and mechanisms for improving lymphoma treatment through microbiome therapy within the human body. It highlights the role of gut microbiota-targeted interventions, such as the use of probiotics and prebiotics, a high-fiber diet, butyrate supplementation, protein consumption, and fecal microbiota transplantation, in modulating the immune system and tumor microenvironment. The diagram also explores the potential of antibiotics to disrupt microbiota balance and the impact of these interventions on immune and epigenetic pathways, ultimately promoting the differentiation of T cells and enhancing antilymphoma responses, while suppressing lymphoma cell proliferation and promoting apoptosis."></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1-17588359251363207/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Possible strategies and mechanisms for microbiome therapy in lymphoma. Gut microbiota-targeted interventions influence lymphoma progression through immune and epigenetic mechanisms. The upper section presents gut microbiota-targeted interventions, including probiotics, prebiotics, high-fiber diet, butyrate supplementation, protein consumption, and fecal microbiota transplantation. These interventions promote beneficial commensal bacteria and their metabolites, while antibiotics may disrupt this balance. The lower section demonstrates the effects of interventions in the tumor microenvironment. <em>Lactobacillus</em> (one of the probiotics) could stimulate the differentiation of T cells into Th1 and Th17 cells, enhancing antilymphoma immune responses. SCFAs improve intestinal barrier integrity, modulate immune function, and induce epigenetic modifications that suppress lymphoma cell proliferation while promoting apoptosis. IPA expands cytotoxic effector CD8+ T cells through epigenetic regulation, which may enhance apoptosis.</p>
<p>Source: Created in BioRender. Peng, S. (2025). <a href="https://BioRender.com/j06w677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://BioRender.com/j06w677</a>.</p>
<p>IPA, indole-3-propionic acid; SCFAs, short-chain fatty acids; Th 1, T helper cell 1; Th 17, T helper cell 17; Th cell, T helper cell; Treg, regulatory T cell.</p></figcaption></figure><section id="section24-17588359251363207"><h4 class="pmc_sec_title">High-fiber diet</h4>
<p>A diet high in fiber, which promotes the production of SCFAs, including butyrate, may potentially have a protective effect against lymphoma by enhancing the apoptosis of tumor cells.<sup><a href="#bibr62-17588359251363207" class="usa-link" aria-describedby="bibr62-17588359251363207">62</a>,<a href="#bibr82-17588359251363207" class="usa-link" aria-describedby="bibr82-17588359251363207">82</a></sup> So it is suggested to incorporate fiber-rich foods into the diet. However, further research is needed to establish definitive dietary recommendations for lymphoma patients.</p></section><section id="section25-17588359251363207"><h4 class="pmc_sec_title">Prebiotics and probiotics</h4>
<p>Prebiotics are indigestible dietary fibers that selectively promote beneficial gut bacteria growth. These specialized fibers serve as a nourishing food source for the probiotics residing in our intestines, further fostering a healthy gut microbiome. Probiotics are live, nonpathogenic microorganisms that, when consumed in adequate quantities, provide beneficial health effects to the host. Numerous studies have already confirmed the roles of prebiotics and probiotics in various diseases. A study showed that restoring the deficient <em>L. johnsonii</em> in the ataxia-telangiectasia mouse model through short-term oral transfer can reduce cancer risk in susceptible individuals.<sup>
<a href="#bibr83-17588359251363207" class="usa-link" aria-describedby="bibr83-17588359251363207">83</a>
</sup> Xu et al.<sup>
<a href="#bibr34-17588359251363207" class="usa-link" aria-describedby="bibr34-17588359251363207">34</a>
</sup> demonstrated that the abundance of <em>L. fermentum</em> significantly increased after chemotherapy and was associated with better treatment response. In vitro experiments showed that <em>Lactobacillus</em> could stimulate the differentiation of T cells into Th1 and Th17 cells, thereby enhancing antilymphoma immune responses.<sup>
<a href="#bibr37-17588359251363207" class="usa-link" aria-describedby="bibr37-17588359251363207">37</a>
</sup> Shi et al.<sup>
<a href="#bibr84-17588359251363207" class="usa-link" aria-describedby="bibr84-17588359251363207">84</a>
</sup> first demonstrated that <em>F. prausnitzii</em> exhibited tumor-suppressing effects in a natural killer/T-cell lymphoma (NKTCL) mouse model, with butyrate as a key mediating metabolite. This suggested that <em>F. prausnitzii</em> could be a promising probiotic candidate for adjunctive therapy in NKTCL. Savitri et al.<sup>
<a href="#bibr85-17588359251363207" class="usa-link" aria-describedby="bibr85-17588359251363207">85</a>
</sup> and Verma et al.<sup>
<a href="#bibr86-17588359251363207" class="usa-link" aria-describedby="bibr86-17588359251363207">86</a>
</sup> suggested that probiotics may enhance HP eradication protocols, potentially through microbial interference and immune modulation. This enhanced bacterial clearance may theoretically reduce HP-associated lymphomagenesis risk, though direct antilymphoma effects remained unproven.</p>
<p>However, careful evaluation and prudent use of probiotics in immunocompromised individuals should be taken seriously. Chemotherapy and HSCT can induce rendered immunosuppressed for a long time. It was reported that one mantle cell lymphoma patient with compromised immunity after HSCT developed <em>Lactobacillus acidophilus</em> sepsis due to excessive consumption of probiotic-rich yogurt.<sup>
<a href="#bibr87-17588359251363207" class="usa-link" aria-describedby="bibr87-17588359251363207">87</a>
</sup> Another Hodgkin’s lymphoma patient with acquired immune deficiency syndrome developed persistent bacteremia after taking a probiotic containing <em>Lactobacillus</em>.<sup>
<a href="#bibr88-17588359251363207" class="usa-link" aria-describedby="bibr88-17588359251363207">88</a>
</sup> Moreover, it was found that the increase in <em>Lactobacillus</em> was positively correlated with the severity of the disease and the risk of chemotherapy side effects in DLBCL patients.<sup>
<a href="#bibr89-17588359251363207" class="usa-link" aria-describedby="bibr89-17588359251363207">89</a>
</sup> A case report indicated that chemotherapy patients may experience bloodstream infections due to commensal bacteria, but were not necessarily related to probiotics.<sup>
<a href="#bibr90-17588359251363207" class="usa-link" aria-describedby="bibr90-17588359251363207">90</a>
</sup> While these reports highlight potential risks, case reports are inherently constrained by low evidence hierarchy and uncontrolled confounding factors. Therefore, whether to administer probiotics, which type of probiotics to administer, and when to administer them should all be carefully considered before use, especially in HSCT patients.</p></section><section id="section26-17588359251363207"><h4 class="pmc_sec_title">FMT</h4>
<p>The clinical advantage of utilizing a solitary bacterial species is constrained.<sup>
<a href="#bibr91-17588359251363207" class="usa-link" aria-describedby="bibr91-17588359251363207">91</a>
</sup> The use of the whole microbiota is known as FMT, which involves extracting functional microbiota from the feces of healthy individuals and then transferring it into the patient’s intestine. It is the most promising strategy to date for effectively rebalancing the composition and function of the gut microbiome. Montassier et al.<sup>
<a href="#bibr92-17588359251363207" class="usa-link" aria-describedby="bibr92-17588359251363207">92</a>
</sup> observed that the pretreatment chemotherapy before bone marrow transplantation led to significant changes in the gut microbiota, including a sharp decline in alpha-diversity, a reduction in anti-inflammatory bacteria, and an increase in harmful bacteria. Several large observational studies showed that low diversity in the gut microbiota prior to allo-HSCT was closely associated with adverse outcomes post-transplantation, including GVHD and future mortality risk.<sup>
<a href="#bibr93-17588359251363207" class="usa-link" aria-describedby="bibr93-17588359251363207">93</a>
</sup> Studies also suggested that it was possible to restore the pre-disease microbiome diversity and composition by collecting fecal samples from patients and reintroducing the microorganisms back into their bodies.<sup>
<a href="#bibr93-17588359251363207" class="usa-link" aria-describedby="bibr93-17588359251363207">93</a>
</sup> Kakihana et al.<sup>
<a href="#bibr94-17588359251363207" class="usa-link" aria-describedby="bibr94-17588359251363207">94</a>
</sup> successfully applied FMT in four patients suffering from steroid-resistant acute GVHD, with no severe FMT-related adverse effects.</p>
<p>However, the potential risks associated with FMT should not be overlooked. DeFilipp et al.<sup>
<a href="#bibr95-17588359251363207" class="usa-link" aria-describedby="bibr95-17588359251363207">95</a>
</sup> reported that two immunocompromised patients developed bloodstream infection of extended-spectrum β-lactamase-producing <em>Escherichia coli</em> following FMT, and the causative strain was linked to the stool of the FMT donor. This observation may be explained by FMT-induced bacterial translocation across the compromised intestinal barrier, potentially driven by local gut mucosal inflammatory responses.<sup>
<a href="#bibr96-17588359251363207" class="usa-link" aria-describedby="bibr96-17588359251363207">96</a>
</sup> In patients undergoing HSCT, particularly during the early post-transplant period when granulocyte reconstitution is incomplete, the risk of intestinal microbiota-derived infections may be significantly elevated. An exploration of how to balance the risks and benefits of FMT in severely immunocompromised patients is needed. Benech et al.<sup>
<a href="#bibr97-17588359251363207" class="usa-link" aria-describedby="bibr97-17588359251363207">97</a>
</sup> recommended a “case-by-case” approach tailored to each patient’s unique risks, values, and preferences to ensure optimal treatment opportunities are not missed. In addition, stringent donor screening protocols are essential to minimize the transmission of potentially pathogenic microorganisms and reduce adverse infectious outcomes.</p></section><section id="section27-17588359251363207"><h4 class="pmc_sec_title">Butyrate supplementation</h4>
<p>The composition and function of the gut microbiome are influenced by various internal and external factors, with diet, environment, and particularly antibiotics among the most prevalent external disruptors.<sup>
<a href="#bibr98-17588359251363207" class="usa-link" aria-describedby="bibr98-17588359251363207">98</a>
</sup> The butyryl-CoA:acetate-CoA transferase pathway serves as the primary route for butyrate production within the human gut microbiota, predominantly relying on gram-positive bacteria for its process.<sup>
<a href="#bibr98-17588359251363207" class="usa-link" aria-describedby="bibr98-17588359251363207">98</a>
</sup> Certain antibiotics may lead to a decrease in essential bacteria that specifically produce butyrate. Butyrate supplementation has been employed to enhance intestinal mucosa integrity and serve as an anti-inflammatory agent in systemic diseases.<sup><a href="#bibr99-17588359251363207" class="usa-link" aria-describedby="bibr99-17588359251363207">99</a>,<a href="#bibr100-17588359251363207" class="usa-link" aria-describedby="bibr100-17588359251363207">100</a></sup> Given its beneficial effects on gut health, administering isolated butyrate during antibiotic use may be advantageous until the recolonization of butyrate-producing bacteria is achieved.<sup>
<a href="#bibr98-17588359251363207" class="usa-link" aria-describedby="bibr98-17588359251363207">98</a>
</sup> Moreover, given its epigenetic modification potential, butyrate may regulate various biological processes, including cell differentiation, proliferation, and apoptosis, as well as lymphoma development and progression. Sodium butyrate administration has been shown to restore the integrity of the intestinal barrier and modulate gut dysbiosis induced by paclitaxel treatment in mice models.<sup>
<a href="#bibr99-17588359251363207" class="usa-link" aria-describedby="bibr99-17588359251363207">99</a>
</sup> As previously noted, lymphoma therapy is also associated with the depletion of butyrate-producing bacteria. By supplementing butyrate levels, sodium butyrate may offer a promising avenue for mitigating chemotherapy-related side effects and improving the treatment response. Further studies are needed to evaluate the safety, optimal dosing, and therapeutic benefits of sodium butyrate supplementation in lymphoma patients. In conclusion, it may be a promising therapeutic target for future treatment and may serve as an adjunctive therapy during lymphoma treatment.</p></section></section></section><section id="section28-17588359251363207"><h2 class="pmc_sec_title">Conclusion</h2>
<p>Although more and more studies have focused on the gut microbiome, the correlation between the gut microbiome and lymphoma remains incompletely characterized. Lymphoma patients exhibit a unique gut microbiota profile that differs from healthy individuals, with certain microbial species and metabolites associated with disease progression, responsiveness to treatment, and the occurrence of adverse reactions. To gain a deeper understanding, further research is necessary to elucidate these associations. Future research should focus on conducting larger cohort studies to identify the specific bacterial species and metabolites that are involved in lymphoma progression, as well as the different treatment approaches. In addition, exploring the potential therapeutic benefits of modulating the particular microbial flora may lead to novel treatment strategies for lymphoma. When using antibiotics, a careful evaluation of their benefits and risks is imperative to minimize disruptions to the gut microbiome while maximizing therapeutic efficacy. By addressing these research gaps, we can pave the way for more personalized and effective therapies that leverage the power of the “gut-microbiome-lymphoma axis.”</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Figure was created with BioRender.com.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn7">
<p><strong>ORCID iDs:</strong> Jiajie Tu <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/080b/12365434/03e617e2a807/10.1177_17588359251363207-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0009-0003-1312-183X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0009-0003-1312-183X</a></p>
<p>Lingzi Yu <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/080b/12365434/03e617e2a807/10.1177_17588359251363207-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0009-0000-5326-8981" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0009-0000-5326-8981</a></p>
<p>Changju Qu <img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/080b/12365434/03e617e2a807/10.1177_17588359251363207-img1.jpg" loading="lazy" alt="Inline graphic">
<a href="https://orcid.org/0000-0003-1803-0008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://orcid.org/0000-0003-1803-0008</a></p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Jiajie Tu, Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.</p>
<p>Lingzi Yu, Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.</p>
<p>Rui Zou, Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.</p>
<p>Jiajie He, Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.</p>
<p>Changju Qu, Department of Hematology, The First Affiliated Hospital of Soochow University, and Jiangsu Institute of Hematology, Suzhou 215000, China; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215000, China.</p></section><section id="section29-17588359251363207"><h2 class="pmc_sec_title">Declarations</h2>
<section id="fn-group2" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn8"><p><strong>Ethics approval and consent to participate:</strong> Not applicable.</p></div>
<div class="fn p" id="fn9"><p><strong>Consent for publication:</strong> Not applicable.</p></div>
<div class="fn p" id="fn10">
<p><strong>Author contributions:</strong>
<strong>Jiajie Tu:</strong> Conceptualization; Visualization; Writing – original draft.</p>
<p><strong>Lingzi Yu:</strong> Conceptualization; Writing – original draft.</p>
<p><strong>Rui Zou:</strong> Conceptualization; Methodology.</p>
<p><strong>Jiajie He:</strong> Conceptualization; Investigation.</p>
<p><strong>Changju Qu:</strong> Conceptualization; Supervision; Writing – review &amp; editing.</p>
</div>
<div class="fn p" id="fn11"><p><strong>Funding:</strong> The authors received no financial support for the research, authorship, and/or publication of this article.</p></div>
<div class="fn p" id="fn12"><p>The authors declare that there is no conflict of interest.</p></div>
<div class="fn p" id="fn13"><p><strong>Availability of data and materials:</strong> No datasets were generated or analyzed during the current study.</p></div>
</div></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bibr1-17588359251363207">
<span class="label">1.</span><cite>
Huang J, Pang WS, Lok V, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol
2022; 15: 57.
</cite> [<a href="https://doi.org/10.1186/s13045-022-01281-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9097358/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35546241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=Incidence,%20mortality,%20risk%20factors,%20and%20trends%20for%20Hodgkin%20lymphoma:%20a%20global%20data%20analysis&amp;author=J%20Huang&amp;author=WS%20Pang&amp;author=V%20Lok&amp;volume=15&amp;publication_year=2022&amp;pages=57&amp;pmid=35546241&amp;doi=10.1186/s13045-022-01281-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr2-17588359251363207">
<span class="label">2.</span><cite>
Zhang N, Wu J, Wang Q, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J
2023; 13: 82.
</cite> [<a href="https://doi.org/10.1038/s41408-023-00853-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10188596/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37193689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20J&amp;title=Global%20burden%20of%20hematologic%20malignancies%20and%20evolution%20patterns%20over%20the%20past%2030%E2%80%89years&amp;author=N%20Zhang&amp;author=J%20Wu&amp;author=Q%20Wang&amp;volume=13&amp;publication_year=2023&amp;pages=82&amp;pmid=37193689&amp;doi=10.1038/s41408-023-00853-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr3-17588359251363207">
<span class="label">3.</span><cite>
Bishop MR, Dickinson M, Purtill D, et al. Second-line Tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med
2022; 386: 629–639.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2116596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34904798/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Second-line%20Tisagenlecleucel%20or%20standard%20care%20in%20aggressive%20B-cell%20lymphoma&amp;author=MR%20Bishop&amp;author=M%20Dickinson&amp;author=D%20Purtill&amp;volume=386&amp;publication_year=2022&amp;pages=629-639&amp;pmid=34904798&amp;doi=10.1056/NEJMoa2116596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr4-17588359251363207">
<span class="label">4.</span><cite>
Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol
2022; 23: 1066–1077.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(22)00339-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35839786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Lisocabtagene%20maraleucel%20as%20second-line%20therapy%20in%20adults%20with%20relapsed%20or%20refractory%20large%20B-cell%20lymphoma%20who%20were%20not%20intended%20for%20haematopoietic%20stem%20cell%20transplantation%20(PILOT):%20an%20open-label,%20phase%202%20study&amp;author=A%20Sehgal&amp;author=D%20Hoda&amp;author=PA%20Riedell&amp;volume=23&amp;publication_year=2022&amp;pages=1066-1077&amp;pmid=35839786&amp;doi=10.1016/S1470-2045(22)00339-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr5-17588359251363207">
<span class="label">5.</span><cite>
Chen DS, Mellman I.
Oncology meets immunology: the cancer-immunity cycle. Immunity
2013; 39: 1–10.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2013.07.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23890059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immunity&amp;title=Oncology%20meets%20immunology:%20the%20cancer-immunity%20cycle&amp;author=DS%20Chen&amp;author=I.%20Mellman&amp;volume=39&amp;publication_year=2013&amp;pages=1-10&amp;pmid=23890059&amp;doi=10.1016/j.immuni.2013.07.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr6-17588359251363207">
<span class="label">6.</span><cite>
Costea PI, Hildebrand F, Arumugam M, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol
2018; 3: 8–16.
</cite> [<a href="https://doi.org/10.1038/s41564-017-0072-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5832044/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29255284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Microbiol&amp;title=Enterotypes%20in%20the%20landscape%20of%20gut%20microbial%20community%20composition&amp;author=PI%20Costea&amp;author=F%20Hildebrand&amp;author=M%20Arumugam&amp;volume=3&amp;publication_year=2018&amp;pages=8-16&amp;pmid=29255284&amp;doi=10.1038/s41564-017-0072-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr7-17588359251363207">
<span class="label">7.</span><cite>
Hooper LV, Littman DR, Macpherson AJ.
Interactions between the microbiota and the immune system. Science
2012; 336: 1268–1273.
</cite> [<a href="https://doi.org/10.1126/science.1223490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4420145/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22674334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Interactions%20between%20the%20microbiota%20and%20the%20immune%20system&amp;author=LV%20Hooper&amp;author=DR%20Littman&amp;author=AJ.%20Macpherson&amp;volume=336&amp;publication_year=2012&amp;pages=1268-1273&amp;pmid=22674334&amp;doi=10.1126/science.1223490&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr8-17588359251363207">
<span class="label">8.</span><cite>
Li J, Butcher J, Mack D, et al. Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease:
Inflamm Bowel Dis
2015; 21: 139–153.
</cite> [<a href="https://doi.org/10.1097/MIB.0000000000000215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25248007/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Inflamm%20Bowel%20Dis&amp;title=Functional%20impacts%20of%20the%20intestinal%20microbiome%20in%20the%20pathogenesis%20of%20inflammatory%20bowel%20disease:&amp;author=J%20Li&amp;author=J%20Butcher&amp;author=D%20Mack&amp;volume=21&amp;publication_year=2015&amp;pages=139-153&amp;pmid=25248007&amp;doi=10.1097/MIB.0000000000000215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr9-17588359251363207">
<span class="label">9.</span><cite>
De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol
2010; 10: 63.
</cite> [<a href="https://doi.org/10.1186/1471-2180-10-63" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2843610/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20181275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Microbiol&amp;title=Intestinal%20dysbiosis%20and%20reduced%20immunoglobulin-coated%20bacteria%20associated%20with%20coeliac%20disease%20in%20children&amp;author=G%20De%20Palma&amp;author=I%20Nadal&amp;author=M%20Medina&amp;volume=10&amp;publication_year=2010&amp;pages=63&amp;pmid=20181275&amp;doi=10.1186/1471-2180-10-63&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr10-17588359251363207">
<span class="label">10.</span><cite>
Clemente JC, Manasson J, Scher JU.
The role of the gut microbiome in systemic inflammatory disease. BMJ
2018; 360: j5145.</cite> [<a href="https://doi.org/10.1136/bmj.j5145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6889978/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29311119/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20role%20of%20the%20gut%20microbiome%20in%20systemic%20inflammatory%20disease&amp;author=JC%20Clemente&amp;author=J%20Manasson&amp;author=JU.%20Scher&amp;volume=360&amp;publication_year=2018&amp;pmid=29311119&amp;doi=10.1136/bmj.j5145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr11-17588359251363207">
<span class="label">11.</span><cite>
Bhatt AP, Redinbo MR, Bultman SJ.
The role of the microbiome in cancer development and therapy. CA Cancer J Clin
2017; 67: 326–344.
</cite> [<a href="https://doi.org/10.3322/caac.21398" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5530583/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28481406/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J%20Clin&amp;title=The%20role%20of%20the%20microbiome%20in%20cancer%20development%20and%20therapy&amp;author=AP%20Bhatt&amp;author=MR%20Redinbo&amp;author=SJ.%20Bultman&amp;volume=67&amp;publication_year=2017&amp;pages=326-344&amp;pmid=28481406&amp;doi=10.3322/caac.21398&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr12-17588359251363207">
<span class="label">12.</span><cite>
Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, et al. Gut microbiota disruption in hematologic cancer therapy: molecular insights and implications for treatment efficacy. Int J Mol Sci
2024; 25: 10255.
</cite> [<a href="https://doi.org/10.3390/ijms251910255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11476909/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39408584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Gut%20microbiota%20disruption%20in%20hematologic%20cancer%20therapy:%20molecular%20insights%20and%20implications%20for%20treatment%20efficacy&amp;author=P%20Guevara-Ram%C3%ADrez&amp;author=S%20Cadena-Ullauri&amp;author=E%20Paz-Cruz&amp;volume=25&amp;publication_year=2024&amp;pages=10255&amp;pmid=39408584&amp;doi=10.3390/ijms251910255&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr13-17588359251363207">
<span class="label">13.</span><cite>
Shi Z, Zhang M.
Emerging roles for the gut microbiome in lymphoid neoplasms. Clin Med Insights Oncol
2021; 15: 11795549211024197.
</cite> [<a href="https://doi.org/10.1177/11795549211024197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8216388/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34211309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Med%20Insights%20Oncol&amp;title=Emerging%20roles%20for%20the%20gut%20microbiome%20in%20lymphoid%20neoplasms&amp;author=Z%20Shi&amp;author=M.%20Zhang&amp;volume=15&amp;publication_year=2021&amp;pages=11795549211024197&amp;pmid=34211309&amp;doi=10.1177/11795549211024197&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr14-17588359251363207">
<span class="label">14.</span><cite>
Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. <em>Helicobacter pylori</em>-associated gastritis and primary B-cell gastric lymphoma. Lancet
1991; 338: 1175–1176.
</cite> [<a href="https://doi.org/10.1016/0140-6736(91)92035-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1682595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Helicobacter%20pylori-associated%20gastritis%20and%20primary%20B-cell%20gastric%20lymphoma&amp;author=AC%20Wotherspoon&amp;author=C%20Ortiz-Hidalgo&amp;author=MR%20Falzon&amp;volume=338&amp;publication_year=1991&amp;pages=1175-1176&amp;pmid=1682595&amp;doi=10.1016/0140-6736(91)92035-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr15-17588359251363207">
<span class="label">15.</span><cite>
Wotherspoon AC, Diss TC, Pan L, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of
Helicobacter pylori. Lancet
1993; 342: 575–577.
</cite> [<a href="https://doi.org/10.1016/0140-6736(93)91409-f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8102719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Helicobacter%20pylori.%20Lancet&amp;title=Regression%20of%20primary%20low-grade%20B-cell%20gastric%20lymphoma%20of%20mucosa-associated%20lymphoid%20tissue%20type%20after%20eradication%20of&amp;author=AC%20Wotherspoon&amp;author=TC%20Diss&amp;author=L%20Pan&amp;volume=342&amp;publication_year=1993&amp;pages=575-577&amp;pmid=8102719&amp;doi=10.1016/0140-6736(93)91409-f&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr16-17588359251363207">
<span class="label">16.</span><cite>
Farinha P, Gascoyne RD.
Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol
2005; 23: 6370–6378.
</cite> [<a href="https://doi.org/10.1200/JCO.2005.05.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16155022/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Molecular%20pathogenesis%20of%20mucosa-associated%20lymphoid%20tissue%20lymphoma&amp;author=P%20Farinha&amp;author=RD.%20Gascoyne&amp;volume=23&amp;publication_year=2005&amp;pages=6370-6378&amp;pmid=16155022&amp;doi=10.1200/JCO.2005.05.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr17-17588359251363207">
<span class="label">17.</span><cite>
Yuan L, Wang W, Zhang W, et al. Gut microbiota in untreated diffuse large B cell lymphoma patients. Front Microbiol
2021; 12: 646361.
</cite> [<a href="https://doi.org/10.3389/fmicb.2021.646361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8076791/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33927704/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Microbiol&amp;title=Gut%20microbiota%20in%20untreated%20diffuse%20large%20B%20cell%20lymphoma%20patients&amp;author=L%20Yuan&amp;author=W%20Wang&amp;author=W%20Zhang&amp;volume=12&amp;publication_year=2021&amp;pages=646361&amp;pmid=33927704&amp;doi=10.3389/fmicb.2021.646361&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr18-17588359251363207">
<span class="label">18.</span><cite>
Yoon SE, Kang W, Choi S, et al. The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma. Blood
2023; 141: 2224–2238.
</cite> [<a href="https://doi.org/10.1182/blood.2022018831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36724450/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20influence%20of%20microbial%20dysbiosis%20on%20immunochemotherapy-related%20efficacy%20and%20safety%20in%20diffuse%20large%20B-cell%20lymphoma&amp;author=SE%20Yoon&amp;author=W%20Kang&amp;author=S%20Choi&amp;volume=141&amp;publication_year=2023&amp;pages=2224-2238&amp;pmid=36724450&amp;doi=10.1182/blood.2022018831&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr19-17588359251363207">
<span class="label">19.</span><cite>
Xu Y, Shi C, Qian J, et al. The gut microbiota is altered significantly in primary diffuse large B‑cell lymphoma patients and relapse refractory diffuse large b‑cell lymphoma patients. Clin Transl Oncol
2025; 27: 2347–2353.
</cite> [<a href="https://doi.org/10.1007/s12094-024-03710-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39320604/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Transl%20Oncol&amp;title=The%20gut%20microbiota%20is%20altered%20significantly%20in%20primary%20diffuse%20large%20B%E2%80%91cell%20lymphoma%20patients%20and%20relapse%20refractory%20diffuse%20large%20b%E2%80%91cell%20lymphoma%20patients&amp;author=Y%20Xu&amp;author=C%20Shi&amp;author=J%20Qian&amp;volume=27&amp;publication_year=2025&amp;pages=2347-2353&amp;pmid=39320604&amp;doi=10.1007/s12094-024-03710-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr20-17588359251363207">
<span class="label">20.</span><cite>
Hooper MJ, LeWitt TM, Pang Y, et al. Gut dysbiosis in cutaneous T-cell lymphoma is characterized by shifts in relative abundances of specific bacterial taxa and decreased diversity in more advanced disease. J Eur Acad Dermatol Venereol
2022; 36: 1552–1563.
</cite> [<a href="https://doi.org/10.1111/jdv.18125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9391260/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35366365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Eur%20Acad%20Dermatol%20Venereol&amp;title=Gut%20dysbiosis%20in%20cutaneous%20T-cell%20lymphoma%20is%20characterized%20by%20shifts%20in%20relative%20abundances%20of%20specific%20bacterial%20taxa%20and%20decreased%20diversity%20in%20more%20advanced%20disease&amp;author=MJ%20Hooper&amp;author=TM%20LeWitt&amp;author=Y%20Pang&amp;volume=36&amp;publication_year=2022&amp;pages=1552-1563&amp;pmid=35366365&amp;doi=10.1111/jdv.18125&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr21-17588359251363207">
<span class="label">21.</span><cite>
Nguyen WQ, Chrisman LP, Enriquez GL, et al. Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment. Front Immunol
2023; 14: 1280205.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1280205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10808320/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38274799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Gut%20microbiota%20analyses%20of%20cutaneous%20T-cell%20lymphoma%20patients%20undergoing%20narrowband%20ultraviolet%20B%20therapy%20reveal%20alterations%20associated%20with%20disease%20treatment&amp;author=WQ%20Nguyen&amp;author=LP%20Chrisman&amp;author=GL%20Enriquez&amp;volume=14&amp;publication_year=2023&amp;pages=1280205&amp;pmid=38274799&amp;doi=10.3389/fimmu.2023.1280205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr22-17588359251363207">
<span class="label">22.</span><cite>
Thomas ZO, Holm J, McCarthy M, et al. Decreased gut short-chain fatty acids in cutaneous T-cell lymphoma: a novel insight. Arch Dermatol Res
2025; 317: 781.
</cite> [<a href="https://doi.org/10.1007/s00403-025-04285-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40411534/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Dermatol%20Res&amp;title=Decreased%20gut%20short-chain%20fatty%20acids%20in%20cutaneous%20T-cell%20lymphoma:%20a%20novel%20insight&amp;author=ZO%20Thomas&amp;author=J%20Holm&amp;author=M%20McCarthy&amp;volume=317&amp;publication_year=2025&amp;pages=781&amp;pmid=40411534&amp;doi=10.1007/s00403-025-04285-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr23-17588359251363207">
<span class="label">23.</span><cite>
Chiba N, Suzuki S, Enriquez-Vera D, et al. Succinic semialdehyde derived from the gut microbiota can promote the proliferation of adult T-cell leukemia/lymphoma cells. Heliyon
2024; 10: e38507.</cite> [<a href="https://doi.org/10.1016/j.heliyon.2024.e38507" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11619966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39640675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heliyon&amp;title=Succinic%20semialdehyde%20derived%20from%20the%20gut%20microbiota%20can%20promote%20the%20proliferation%20of%20adult%20T-cell%20leukemia/lymphoma%20cells&amp;author=N%20Chiba&amp;author=S%20Suzuki&amp;author=D%20Enriquez-Vera&amp;volume=10&amp;publication_year=2024&amp;pmid=39640675&amp;doi=10.1016/j.heliyon.2024.e38507&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr24-17588359251363207">
<span class="label">24.</span><cite>
Zeze K, Hirana A, Torisu T, et al. Mucosal dysbiosis in patients with gastrointestinal follicular lymphoma. Hematol Oncol
2020; 38(2): 181–188.
</cite> [<a href="https://doi.org/10.1002/hon.2717" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31990065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol&amp;title=Mucosal%20dysbiosis%20in%20patients%20with%20gastrointestinal%20follicular%20lymphoma&amp;author=K%20Zeze&amp;author=A%20Hirana&amp;author=T%20Torisu&amp;volume=38&amp;issue=2&amp;publication_year=2020&amp;pages=181-188&amp;pmid=31990065&amp;doi=10.1002/hon.2717&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr25-17588359251363207">
<span class="label">25.</span><cite>
Xu Z-F, Zhao D, Wei C, et al. Characteristics and prognostic value of gut microbiota in follicular lymphoma. Oncol Lett
2024; 27: 207.
</cite> [<a href="https://doi.org/10.3892/ol.2024.14340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10973929/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38549803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncol%20Lett&amp;title=Characteristics%20and%20prognostic%20value%20of%20gut%20microbiota%20in%20follicular%20lymphoma&amp;author=Z-F%20Xu&amp;author=D%20Zhao&amp;author=C%20Wei&amp;volume=27&amp;publication_year=2024&amp;pages=207&amp;pmid=38549803&amp;doi=10.3892/ol.2024.14340&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr26-17588359251363207">
<span class="label">26.</span><cite>
Kang Z, Zhang R, Li S, et al. Preliminary investigation of gut microbiota and associated metabolic pathways in the pathogenesis of primary central nervous system lymphoma. Front Oncol
2025; 15: 1548146.
</cite> [<a href="https://doi.org/10.3389/fonc.2025.1548146" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12000031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40242244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Preliminary%20investigation%20of%20gut%20microbiota%20and%20associated%20metabolic%20pathways%20in%20the%20pathogenesis%20of%20primary%20central%20nervous%20system%20lymphoma&amp;author=Z%20Kang&amp;author=R%20Zhang&amp;author=S%20Li&amp;volume=15&amp;publication_year=2025&amp;pages=1548146&amp;pmid=40242244&amp;doi=10.3389/fonc.2025.1548146&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr27-17588359251363207">
<span class="label">27.</span><cite>
Liang J, Liu G, Wang W, et al. Causal relationships between gut microbiota and lymphoma: a bidirectional Mendelian randomization study. Front Cell Infect Microbiol
2024; 14: 1374775.
</cite> [<a href="https://doi.org/10.3389/fcimb.2024.1374775" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11128559/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38803568/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Cell%20Infect%20Microbiol&amp;title=Causal%20relationships%20between%20gut%20microbiota%20and%20lymphoma:%20a%20bidirectional%20Mendelian%20randomization%20study&amp;author=J%20Liang&amp;author=G%20Liu&amp;author=W%20Wang&amp;volume=14&amp;publication_year=2024&amp;pages=1374775&amp;pmid=38803568&amp;doi=10.3389/fcimb.2024.1374775&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr28-17588359251363207">
<span class="label">28.</span><cite>
Jiang P, Yu F, Zhou X, et al. Dissecting causal links between gut microbiota, inflammatory cytokines, and DLBCL: a Mendelian randomization study. Blood Adv
2024; 8: 2268–2278.
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2023012246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11117010/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38507680/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Dissecting%20causal%20links%20between%20gut%20microbiota,%20inflammatory%20cytokines,%20and%20DLBCL:%20a%20Mendelian%20randomization%20study&amp;author=P%20Jiang&amp;author=F%20Yu&amp;author=X%20Zhou&amp;volume=8&amp;publication_year=2024&amp;pages=2268-2278&amp;pmid=38507680&amp;doi=10.1182/bloodadvances.2023012246&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr29-17588359251363207">
<span class="label">29.</span><cite>
Li B, Han Y, Fu Z, et al. The causal relationship between gut microbiota and lymphoma: a two-sample Mendelian randomization study. Front Immunol
2024; 15: 1397485.
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1397485" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11106390/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38774867/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=The%20causal%20relationship%20between%20gut%20microbiota%20and%20lymphoma:%20a%20two-sample%20Mendelian%20randomization%20study&amp;author=B%20Li&amp;author=Y%20Han&amp;author=Z%20Fu&amp;volume=15&amp;publication_year=2024&amp;pages=1397485&amp;pmid=38774867&amp;doi=10.3389/fimmu.2024.1397485&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr30-17588359251363207">
<span class="label">30.</span><cite>
Huang R, Liu B, Zhang W, et al. Identifying the causal relationship between gut microbiota and lymphoma disease: a Mendelian randomization study and meta-analysis. Arch Med Sci. Epub ahead of print February 2025. DOI: 10.5114/aoms/199574.</cite> [<a href="https://doi.org/10.5114/aoms/199574" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Med%20Sci&amp;title=Identifying%20the%20causal%20relationship%20between%20gut%20microbiota%20and%20lymphoma%20disease:%20a%20Mendelian%20randomization%20study%20and%20meta-analysis&amp;author=R%20Huang&amp;author=B%20Liu&amp;author=W%20Zhang&amp;doi=10.5114/aoms/199574&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr31-17588359251363207">
<span class="label">31.</span><cite>
Li M, Wang L, Peng Z, et al. Causal associations of gut microbiota species with lymphoma: a two-sample Mendelian randomization study. Hematol Oncol
2025; 43: e70046.</cite> [<a href="https://doi.org/10.1002/hon.70046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39950509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol&amp;title=Causal%20associations%20of%20gut%20microbiota%20species%20with%20lymphoma:%20a%20two-sample%20Mendelian%20randomization%20study&amp;author=M%20Li&amp;author=L%20Wang&amp;author=Z%20Peng&amp;volume=43&amp;publication_year=2025&amp;pmid=39950509&amp;doi=10.1002/hon.70046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr32-17588359251363207">
<span class="label">32.</span><cite>
Laoguo S, Tang J, Xu X, et al. Causal relationship between gut microbiota and malignant lymphoma: a two-way two-sample Mendelian randomization study. Transl Cancer Res
2025; 14: 1982–1994.
</cite> [<a href="https://doi.org/10.21037/tcr-2025-303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11985171/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40225002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl%20Cancer%20Res&amp;title=Causal%20relationship%20between%20gut%20microbiota%20and%20malignant%20lymphoma:%20a%20two-way%20two-sample%20Mendelian%20randomization%20study&amp;author=S%20Laoguo&amp;author=J%20Tang&amp;author=X%20Xu&amp;volume=14&amp;publication_year=2025&amp;pages=1982-1994&amp;pmid=40225002&amp;doi=10.21037/tcr-2025-303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr33-17588359251363207">
<span class="label">33.</span><cite>
Diefenbach CS, Peters BA, Li H, et al. Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. Blood Adv
2021; 5: 1194–1198.
</cite> [<a href="https://doi.org/10.1182/bloodadvances.2020003129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7948261/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33635332/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Adv&amp;title=Microbial%20dysbiosis%20is%20associated%20with%20aggressive%20histology%20and%20adverse%20clinical%20outcome%20in%20B-cell%20non-Hodgkin%20lymphoma&amp;author=CS%20Diefenbach&amp;author=BA%20Peters&amp;author=H%20Li&amp;volume=5&amp;publication_year=2021&amp;pages=1194-1198&amp;pmid=33635332&amp;doi=10.1182/bloodadvances.2020003129&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr34-17588359251363207">
<span class="label">34.</span><cite>
Xu Z-F, Yuan L, Zhang Y, et al. The gut microbiome correlated to chemotherapy efficacy in diffuse large B-cell lymphoma patients. Hematol Rep
2024; 16: 63–75.</cite> [<a href="https://doi.org/10.3390/hematolrep16010007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10885071/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38390939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Rep&amp;title=The%20gut%20microbiome%20correlated%20to%20chemotherapy%20efficacy%20in%20diffuse%20large%20B-cell%20lymphoma%20patients&amp;author=Z-F%20Xu&amp;author=L%20Yuan&amp;author=Y%20Zhang&amp;volume=16&amp;publication_year=2024&amp;pages=63-75&amp;pmid=38390939&amp;doi=10.3390/hematolrep16010007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr35-17588359251363207">
<span class="label">35.</span><cite>
Hernández-Verdin I, Kirasic E, Mokhtari K, et al. Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: an ancillary study from the BLOCAGE trial. Neuro Oncol. Epub ahead of print March 2025. DOI: 10.1093/neuonc/noaf059.</cite> [<a href="https://doi.org/10.1093/neuonc/noaf059" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40048707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuro%20Oncol&amp;title=Gut%20microbiome%20modulates%20the%20outcome%20in%20primary%20central%20nervous%20system%20lymphoma%20patients%20undergoing%20chemotherapy:%20an%20ancillary%20study%20from%20the%20BLOCAGE%20trial&amp;author=I%20Hern%C3%A1ndez-Verdin&amp;author=E%20Kirasic&amp;author=K%20Mokhtari&amp;pmid=40048707&amp;doi=10.1093/neuonc/noaf059&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr36-17588359251363207">
<span class="label">36.</span><cite>
He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab
2021; 33: 988–1000.e7.</cite> [<a href="https://doi.org/10.1016/j.cmet.2021.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33761313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Metab&amp;title=Gut%20microbial%20metabolites%20facilitate%20anticancer%20therapy%20efficacy%20by%20modulating%20cytotoxic%20CD8+%20T%20cell%20immunity&amp;author=Y%20He&amp;author=L%20Fu&amp;author=Y%20Li&amp;volume=33&amp;publication_year=2021&amp;pmid=33761313&amp;doi=10.1016/j.cmet.2021.03.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr37-17588359251363207">
<span class="label">37.</span><cite>
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science
2013; 342: 971–976.
</cite> [<a href="https://doi.org/10.1126/science.1240537" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4048947/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24264990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=The%20intestinal%20microbiota%20modulates%20the%20anticancer%20immune%20effects%20of%20cyclophosphamide&amp;author=S%20Viaud&amp;author=F%20Saccheri&amp;author=G%20Mignot&amp;volume=342&amp;publication_year=2013&amp;pages=971-976&amp;pmid=24264990&amp;doi=10.1126/science.1240537&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr38-17588359251363207">
<span class="label">38.</span><cite>
Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology
2016; 5: e1150399.</cite> [<a href="https://doi.org/10.1080/2162402X.2016.1150399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4938364/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27471619/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoimmunology&amp;title=Efficacy%20of%20antineoplastic%20treatment%20is%20associated%20with%20the%20use%20of%20antibiotics%20that%20modulate%20intestinal%20microbiota&amp;author=N%20Pflug&amp;author=S%20Kluth&amp;author=JJ%20Vehreschild&amp;volume=5&amp;publication_year=2016&amp;pmid=27471619&amp;doi=10.1080/2162402X.2016.1150399&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr39-17588359251363207">
<span class="label">39.</span><cite>
Khan N, Lindner S, Gomes ALC, et al. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood
2021; 137: 1527–1537.
</cite> [<a href="https://doi.org/10.1182/blood.2020006923" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7976512/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33512409/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Fecal%20microbiota%20diversity%20disruption%20and%20clinical%20outcomes%20after%20auto-HCT:%20a%20multicenter%20observational%20study&amp;author=N%20Khan&amp;author=S%20Lindner&amp;author=ALC%20Gomes&amp;volume=137&amp;publication_year=2021&amp;pages=1527-1537&amp;pmid=33512409&amp;doi=10.1182/blood.2020006923&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr40-17588359251363207">
<span class="label">40.</span><cite>
Qi L, Peng J, Huang X, et al. Longitudinal dynamics of gut microbiota in the pathogenesis of acute graft-versus-host disease. Cancer Med
2023; 12: 21567–21578.
</cite> [<a href="https://doi.org/10.1002/cam4.6557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10757094/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38053512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Med&amp;title=Longitudinal%20dynamics%20of%20gut%20microbiota%20in%20the%20pathogenesis%20of%20acute%20graft-versus-host%20disease&amp;author=L%20Qi&amp;author=J%20Peng&amp;author=X%20Huang&amp;volume=12&amp;publication_year=2023&amp;pages=21567-21578&amp;pmid=38053512&amp;doi=10.1002/cam4.6557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr41-17588359251363207">
<span class="label">41.</span><cite>
Artacho A, González-Torres C, Gómez-Cebrián N, et al. Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases. Microbiome
2024; 12: 229.
</cite> [<a href="https://doi.org/10.1186/s40168-024-01948-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11542268/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39511587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microbiome&amp;title=Multimodal%20analysis%20identifies%20microbiome%20changes%20linked%20to%20stem%20cell%20transplantation-associated%20diseases&amp;author=A%20Artacho&amp;author=C%20Gonz%C3%A1lez-Torres&amp;author=N%20G%C3%B3mez-Cebri%C3%A1n&amp;volume=12&amp;publication_year=2024&amp;pages=229&amp;pmid=39511587&amp;doi=10.1186/s40168-024-01948-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr42-17588359251363207">
<span class="label">42.</span><cite>
Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther
2015; 42: 515–528.
</cite> [<a href="https://doi.org/10.1111/apt.13302" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26147207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aliment%20Pharmacol%20Ther&amp;title=Chemotherapy-driven%20dysbiosis%20in%20the%20intestinal%20microbiome&amp;author=E%20Montassier&amp;author=T%20Gastinne&amp;author=P%20Vangay&amp;volume=42&amp;publication_year=2015&amp;pages=515-528&amp;pmid=26147207&amp;doi=10.1111/apt.13302&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr43-17588359251363207">
<span class="label">43.</span><cite>
Montassier E, Al-Ghalith GA, Ward T, et al. Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection. Genome Med
2016; 8: 49.
</cite> [<a href="https://doi.org/10.1186/s13073-016-0301-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4848771/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27121964/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Med&amp;title=Pretreatment%20gut%20microbiome%20predicts%20chemotherapy-related%20bloodstream%20infection&amp;author=E%20Montassier&amp;author=GA%20Al-Ghalith&amp;author=T%20Ward&amp;volume=8&amp;publication_year=2016&amp;pages=49&amp;pmid=27121964&amp;doi=10.1186/s13073-016-0301-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr44-17588359251363207">
<span class="label">44.</span><cite>
Kaundal S, Patil AN, Ks L, et al. A role for diet and gut microbiota metabolites in autologous hematopoietic cell transplant recipients. Blood Cell Ther
2024; 7: 101–105.
</cite> [<a href="https://doi.org/10.31547/bct-2024-007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11620986/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39651062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cell%20Ther&amp;title=A%20role%20for%20diet%20and%20gut%20microbiota%20metabolites%20in%20autologous%20hematopoietic%20cell%20transplant%20recipients&amp;author=S%20Kaundal&amp;author=AN%20Patil&amp;author=L%20Ks&amp;volume=7&amp;publication_year=2024&amp;pages=101-105&amp;pmid=39651062&amp;doi=10.31547/bct-2024-007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr45-17588359251363207">
<span class="label">45.</span><cite>
Shouval R, Waters NR, Gomes ALC, et al. Conditioning regimens are associated with distinct patterns of microbiota injury in allogeneic hematopoietic cell transplantation. Clin Cancer Res
2023; 29: 165–173.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-1254" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9812902/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36322005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Conditioning%20regimens%20are%20associated%20with%20distinct%20patterns%20of%20microbiota%20injury%20in%20allogeneic%20hematopoietic%20cell%20transplantation&amp;author=R%20Shouval&amp;author=NR%20Waters&amp;author=ALC%20Gomes&amp;volume=29&amp;publication_year=2023&amp;pages=165-173&amp;pmid=36322005&amp;doi=10.1158/1078-0432.CCR-22-1254&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr46-17588359251363207">
<span class="label">46.</span><cite>
Devaux CA, Million M, Raoult D.
The butyrogenic and lactic bacteria of the gut microbiota determine the outcome of allogenic hematopoietic cell transplant. Front Microbiol
2020; 11: 1642.
</cite> [<a href="https://doi.org/10.3389/fmicb.2020.01642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7387665/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32793150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Microbiol&amp;title=The%20butyrogenic%20and%20lactic%20bacteria%20of%20the%20gut%20microbiota%20determine%20the%20outcome%20of%20allogenic%20hematopoietic%20cell%20transplant&amp;author=CA%20Devaux&amp;author=M%20Million&amp;author=D.%20Raoult&amp;volume=11&amp;publication_year=2020&amp;pages=1642&amp;pmid=32793150&amp;doi=10.3389/fmicb.2020.01642&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr47-17588359251363207">
<span class="label">47.</span><cite>
Wu K, Yuan Y, Yu H, et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood
2020; 136: 501–515.
</cite> [<a href="https://doi.org/10.1182/blood.2019003990" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7378459/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32291445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20gut%20microbial%20metabolite%20trimethylamine%20N-oxide%20aggravates%20GVHD%20by%20inducing%20M1%20macrophage%20polarization%20in%20mice&amp;author=K%20Wu&amp;author=Y%20Yuan&amp;author=H%20Yu&amp;volume=136&amp;publication_year=2020&amp;pages=501-515&amp;pmid=32291445&amp;doi=10.1182/blood.2019003990&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr48-17588359251363207">
<span class="label">48.</span><cite>
Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med
2020; 382: 822–834.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1900623" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7534690/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32101664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Microbiota%20as%20predictor%20of%20mortality%20in%20allogeneic%20hematopoietic-cell%20transplantation&amp;author=JU%20Peled&amp;author=ALC%20Gomes&amp;author=SM%20Devlin&amp;volume=382&amp;publication_year=2020&amp;pages=822-834&amp;pmid=32101664&amp;doi=10.1056/NEJMoa1900623&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr49-17588359251363207">
<span class="label">49.</span><cite>
Weber D, Hiergeist A, Weber M, et al. Restrictive versus permissive use of broad-spectrum antibiotics in patients receiving allogeneic stem cell transplantation and with early fever due to cytokine release syndrome: evidence for beneficial microbiota protection without increase in infectious complications. Clin Infect Dis
2023; 77: 1432–1439.
</cite> [<a href="https://doi.org/10.1093/cid/ciad389" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37386935/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Restrictive%20versus%20permissive%20use%20of%20broad-spectrum%20antibiotics%20in%20patients%20receiving%20allogeneic%20stem%20cell%20transplantation%20and%20with%20early%20fever%20due%20to%20cytokine%20release%20syndrome:%20evidence%20for%20beneficial%20microbiota%20protection%20without%20increase%20in%20infectious%20complications&amp;author=D%20Weber&amp;author=A%20Hiergeist&amp;author=M%20Weber&amp;volume=77&amp;publication_year=2023&amp;pages=1432-1439&amp;pmid=37386935&amp;doi=10.1093/cid/ciad389&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr50-17588359251363207">
<span class="label">50.</span><cite>
Hayase E, Hayase T, Mukherjee A, et al. <em>Bacteroides ovatus</em> alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq
2023; rs.3.rs-2460097.</cite> [<a href="https://doi.org/10.1016/j.chom.2024.08.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11441101/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39214085/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Res%20Sq&amp;title=Bacteroides%20ovatus%20alleviates%20dysbiotic%20microbiota-induced%20intestinal%20graft-versus-host%20disease&amp;author=E%20Hayase&amp;author=T%20Hayase&amp;author=A%20Mukherjee&amp;publication_year=2023&amp;pmid=39214085&amp;doi=10.1016/j.chom.2024.08.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr51-17588359251363207">
<span class="label">51.</span><cite>
Casadei B, Conti G, Barone M, et al. Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—the MicroLinf study. Hematol Oncol
2024; 42: e3301.</cite> [<a href="https://doi.org/10.1002/hon.3301" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39104142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol&amp;title=Role%20of%20gut%20microbiome%20in%20the%20outcome%20of%20lymphoma%20patients%20treated%20with%20checkpoint%20inhibitors%E2%80%94the%20MicroLinf%20study&amp;author=B%20Casadei&amp;author=G%20Conti&amp;author=M%20Barone&amp;volume=42&amp;publication_year=2024&amp;pmid=39104142&amp;doi=10.1002/hon.3301&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr52-17588359251363207">
<span class="label">52.</span><cite>
Hwang SR, Higgins A, Castillo Almeida NE, et al. Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leuk Lymphoma
2021; 62: 247–251.
</cite> [<a href="https://doi.org/10.1080/10428194.2020.1827250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33021136/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Lymphoma&amp;title=Effect%20of%20antibiotic%20use%20on%20outcomes%20in%20patients%20with%20Hodgkin%20lymphoma%20treated%20with%20immune%20checkpoint%20inhibitors&amp;author=SR%20Hwang&amp;author=A%20Higgins&amp;author=NE%20Castillo%20Almeida&amp;volume=62&amp;publication_year=2021&amp;pages=247-251&amp;pmid=33021136&amp;doi=10.1080/10428194.2020.1827250&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr53-17588359251363207">
<span class="label">53.</span><cite>
Yang H, Green MR.
Harnessing lymphoma epigenetics to improve therapies. Hematology
2020; 2020: 95–100.
</cite> [<a href="https://doi.org/10.1182/hematology.2020006908" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7727577/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33275741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematology&amp;title=Harnessing%20lymphoma%20epigenetics%20to%20improve%20therapies&amp;author=H%20Yang&amp;author=MR.%20Green&amp;volume=2020&amp;publication_year=2020&amp;pages=95-100&amp;pmid=33275741&amp;doi=10.1182/hematology.2020006908&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr54-17588359251363207">
<span class="label">54.</span><cite>
Costa PM, da S, Sales SLA, Pinheiro DP, et al. Epigenetic reprogramming in cancer: from diagnosis to treatment. Front Cell Dev Biol
2023; 11: 1116805.
</cite> [<a href="https://doi.org/10.3389/fcell.2023.1116805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9974167/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36866275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Cell%20Dev%20Biol&amp;title=Epigenetic%20reprogramming%20in%20cancer:%20from%20diagnosis%20to%20treatment&amp;author=PM%20Costa&amp;author=S%20da&amp;author=SLA%20Sales&amp;author=DP%20Pinheiro&amp;volume=11&amp;publication_year=2023&amp;pages=1116805&amp;pmid=36866275&amp;doi=10.3389/fcell.2023.1116805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr55-17588359251363207">
<span class="label">55.</span><cite>
Clozel T, Yang S, Elstrom RL, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov
2013; 3: 1002–1019.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-13-0117" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3770813/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23955273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Mechanism-based%20epigenetic%20chemosensitization%20therapy%20of%20diffuse%20large%20B-cell%20lymphoma&amp;author=T%20Clozel&amp;author=S%20Yang&amp;author=RL%20Elstrom&amp;volume=3&amp;publication_year=2013&amp;pages=1002-1019&amp;pmid=23955273&amp;doi=10.1158/2159-8290.CD-13-0117&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr56-17588359251363207">
<span class="label">56.</span><cite>
Cerchietti L, Leonard JP.
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology Am Soc Hematol Educ Program
2013; 2013: 591–595.
</cite> [<a href="https://doi.org/10.1182/asheducation-2013.1.591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24319236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematology%20Am%20Soc%20Hematol%20Educ%20Program&amp;title=Targeting%20the%20epigenome%20and%20other%20new%20strategies%20in%20diffuse%20large%20B-cell%20lymphoma:%20beyond%20R-CHOP&amp;author=L%20Cerchietti&amp;author=JP.%20Leonard&amp;volume=2013&amp;publication_year=2013&amp;pages=591-595&amp;pmid=24319236&amp;doi=10.1182/asheducation-2013.1.591&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr57-17588359251363207">
<span class="label">57.</span><cite>
Zhang H, Chi F, Qin K, et al. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway. Mol Med Rep
2021; 23: 308.
</cite> [<a href="https://doi.org/10.3892/mmr.2021.11947" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7974270/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33649847/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Med%20Rep&amp;title=Chidamide%20induces%20apoptosis%20in%20DLBCL%20cells%20by%20suppressing%20the%20HDACs/STAT3/Bcl%E2%80%912%20pathway&amp;author=H%20Zhang&amp;author=F%20Chi&amp;author=K%20Qin&amp;volume=23&amp;publication_year=2021&amp;pages=308&amp;pmid=33649847&amp;doi=10.3892/mmr.2021.11947&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr58-17588359251363207">
<span class="label">58.</span><cite>
Wang W, Wang J, Li Z, et al. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL. Oncol Rep
2016; 35: 139–146.
</cite> [<a href="https://doi.org/10.3892/or.2015.4347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26498513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncol%20Rep&amp;title=Promoter%20hypermethylation%20of%20PTPL1,%20PTPN6,%20DAPK,%20p16%20and%205-azacitidine%20inhibits%20growth%20in%20DLBCL&amp;author=W%20Wang&amp;author=J%20Wang&amp;author=Z%20Li&amp;volume=35&amp;publication_year=2016&amp;pages=139-146&amp;pmid=26498513&amp;doi=10.3892/or.2015.4347&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr59-17588359251363207">
<span class="label">59.</span><cite>
Pera B, Tang T, Marullo R, et al. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenetics
2016; 8: 79.
</cite> [<a href="https://doi.org/10.1186/s13148-016-0245-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4957280/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27453763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Epigenetics&amp;title=Combinatorial%20epigenetic%20therapy%20in%20diffuse%20large%20B%20cell%20lymphoma%20pre-clinical%20models%20and%20patients&amp;author=B%20Pera&amp;author=T%20Tang&amp;author=R%20Marullo&amp;volume=8&amp;publication_year=2016&amp;pages=79&amp;pmid=27453763&amp;doi=10.1186/s13148-016-0245-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr60-17588359251363207">
<span class="label">60.</span><cite>
Qu C, Ping N, Kong D, et al. Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy. Hematol Oncol
2022; 40: 914–921.
</cite> [<a href="https://doi.org/10.1002/hon.3052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35856472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematol%20Oncol&amp;title=Dual%20epigenetic%20agents%20plus%20rituximab-gemcitabine-oxaliplatin%20as%20salvage%20treatment%20in%20relapsed/refractory%20diffuse%20large%20B-cell%20lymphoma%20patients%20failure%20of%20salvage%20chemotherapy&amp;author=C%20Qu&amp;author=N%20Ping&amp;author=D%20Kong&amp;volume=40&amp;publication_year=2022&amp;pages=914-921&amp;pmid=35856472&amp;doi=10.1002/hon.3052&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr61-17588359251363207">
<span class="label">61.</span><cite>
van der Hee B, Wells JM. Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol
2021; 29: 700–712.
</cite> [<a href="https://doi.org/10.1016/j.tim.2021.02.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33674141/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Microbiol&amp;title=Microbial%20regulation%20of%20host%20physiology%20by%20short-chain%20fatty%20acids&amp;author=B%20van%20der%20Hee&amp;author=JM%20Wells&amp;volume=29&amp;publication_year=2021&amp;pages=700-712&amp;pmid=33674141&amp;doi=10.1016/j.tim.2021.02.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr62-17588359251363207">
<span class="label">62.</span><cite>
Wei W, Sun W, Yu S, et al. Butyrate production from high-fiber diet protects against lymphoma tumor. Leuk Lymphoma
2016; 57: 2401–2408.
</cite> [<a href="https://doi.org/10.3109/10428194.2016.1144879" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26885564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Leuk%20Lymphoma&amp;title=Butyrate%20production%20from%20high-fiber%20diet%20protects%20against%20lymphoma%20tumor&amp;author=W%20Wei&amp;author=W%20Sun&amp;author=S%20Yu&amp;volume=57&amp;publication_year=2016&amp;pages=2401-2408&amp;pmid=26885564&amp;doi=10.3109/10428194.2016.1144879&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr63-17588359251363207">
<span class="label">63.</span><cite>
Lin Z, Mao D, Jin C, et al. The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma. Front Immunol
2023; 14: 1105293.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1105293" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9986463/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36891300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=The%20gut%20microbiota%20correlate%20with%20the%20disease%20characteristics%20and%20immune%20status%20of%20patients%20with%20untreated%20diffuse%20large%20B-cell%20lymphoma&amp;author=Z%20Lin&amp;author=D%20Mao&amp;author=C%20Jin&amp;volume=14&amp;publication_year=2023&amp;pages=1105293&amp;pmid=36891300&amp;doi=10.3389/fimmu.2023.1105293&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr64-17588359251363207">
<span class="label">64.</span><cite>
Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med
2022; 28: 713–723.
</cite> [<a href="https://doi.org/10.1038/s41591-022-01702-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9434490/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35288695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Gut%20microbiome%20correlates%20of%20response%20and%20toxicity%20following%20anti-CD19%20CAR%20T%20cell%20therapy&amp;author=M%20Smith&amp;author=A%20Dai&amp;author=G%20Ghilardi&amp;volume=28&amp;publication_year=2022&amp;pages=713-723&amp;pmid=35288695&amp;doi=10.1038/s41591-022-01702-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr65-17588359251363207">
<span class="label">65.</span><cite>
Jia D, Wang Q, Qi Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell
2024; 187: 1651–1665.e21.</cite> [<a href="https://doi.org/10.1016/j.cell.2024.02.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38490195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Microbial%20metabolite%20enhances%20immunotherapy%20efficacy%20by%20modulating%20T%20cell%20stemness%20in%20pan-cancer&amp;author=D%20Jia&amp;author=Q%20Wang&amp;author=Y%20Qi&amp;volume=187&amp;publication_year=2024&amp;pmid=38490195&amp;doi=10.1016/j.cell.2024.02.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr66-17588359251363207">
<span class="label">66.</span><cite>
Jia D, Kuang Z, Wang L.
The role of microbial indole metabolites in tumor. Gut Microbes
2024; 16: 2409209.
</cite> [<a href="https://doi.org/10.1080/19490976.2024.2409209" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11445886/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39353090/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut%20Microbes&amp;title=The%20role%20of%20microbial%20indole%20metabolites%20in%20tumor&amp;author=D%20Jia&amp;author=Z%20Kuang&amp;author=L.%20Wang&amp;volume=16&amp;publication_year=2024&amp;pages=2409209&amp;pmid=39353090&amp;doi=10.1080/19490976.2024.2409209&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr67-17588359251363207">
<span class="label">67.</span><cite>
Ragheb R, Venton G, Chelbi R, et al. Vorinostat and mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach. Arch Dermatol Res
2017; 309: 611–623.
</cite> [<a href="https://doi.org/10.1007/s00403-017-1761-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28695331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Dermatol%20Res&amp;title=Vorinostat%20and%20mithramycin%20A%20in%20combination%20therapy%20as%20an%20interesting%20strategy%20for%20the%20treatment%20of%20S%C3%A9zary%20T%20lymphoma:%20a%20transcriptomic%20approach&amp;author=R%20Ragheb&amp;author=G%20Venton&amp;author=R%20Chelbi&amp;volume=309&amp;publication_year=2017&amp;pages=611-623&amp;pmid=28695331&amp;doi=10.1007/s00403-017-1761-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr68-17588359251363207">
<span class="label">68.</span><cite>
Cappell KM, Kochenderfer JN.
Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol
2023; 20: 359–371.
</cite> [<a href="https://doi.org/10.1038/s41571-023-00754-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10100620/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37055515/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Long-term%20outcomes%20following%20CAR%20T%20cell%20therapy:%20what%20we%20know%20so%20far&amp;author=KM%20Cappell&amp;author=JN.%20Kochenderfer&amp;volume=20&amp;publication_year=2023&amp;pages=359-371&amp;pmid=37055515&amp;doi=10.1038/s41571-023-00754-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr69-17588359251363207">
<span class="label">69.</span><cite>
Yin Z, Zhang Y, Wang X.
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomark Res
2021; 9: 58.
</cite> [<a href="https://doi.org/10.1186/s40364-021-00309-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8278776/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34256851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomark%20Res&amp;title=Advances%20in%20chimeric%20antigen%20receptor%20T-cell%20therapy%20for%20B-cell%20non-Hodgkin%20lymphoma&amp;author=Z%20Yin&amp;author=Y%20Zhang&amp;author=X.%20Wang&amp;volume=9&amp;publication_year=2021&amp;pages=58&amp;pmid=34256851&amp;doi=10.1186/s40364-021-00309-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr70-17588359251363207">
<span class="label">70.</span><cite>
Grinda T, Brouard J, Tran D, et al. [Mechanisms of resistance and escape to CAR-T cells]. Bull Cancer
2021; 108: S128–S140.</cite> [<a href="https://doi.org/10.1016/j.bulcan.2021.09.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34920795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bull%20Cancer&amp;title=%5BMechanisms%20of%20resistance%20and%20escape%20to%20CAR-T%20cells%5D&amp;author=T%20Grinda&amp;author=J%20Brouard&amp;author=D%20Tran&amp;volume=108&amp;publication_year=2021&amp;pmid=34920795&amp;doi=10.1016/j.bulcan.2021.09.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr71-17588359251363207">
<span class="label">71.</span><cite>
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol
2019; 20: 31–42.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(18)30864-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6733402/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30518502/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Long-term%20safety%20and%20activity%20of%20axicabtagene%20ciloleucel%20in%20refractory%20large%20B-cell%20lymphoma%20(ZUMA-1):%20a%20single-arm,%20multicentre,%20phase%201%E2%80%932%20trial&amp;author=FL%20Locke&amp;author=A%20Ghobadi&amp;author=CA%20Jacobson&amp;volume=20&amp;publication_year=2019&amp;pages=31-42&amp;pmid=30518502&amp;doi=10.1016/S1470-2045(18)30864-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr72-17588359251363207">
<span class="label">72.</span><cite>
Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book
2019; 39: 433–444.
</cite> [<a href="https://doi.org/10.1200/EDBK_238691" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31099694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Soc%20Clin%20Oncol%20Educ%20Book&amp;title=The%20other%20side%20of%20CAR%20T-cell%20therapy:%20cytokine%20release%20syndrome,%20neurologic%20toxicity,%20and%20financial%20burden&amp;author=B%20Santomasso&amp;author=C%20Bachier&amp;author=J%20Westin&amp;volume=39&amp;publication_year=2019&amp;pages=433-444&amp;pmid=31099694&amp;doi=10.1200/EDBK_238691&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr73-17588359251363207">
<span class="label">73.</span><cite>
Zhang P-F, Xie D.
Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
Front Immunol
2024; 15: 1362133.
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1362133" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10978602/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38558812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Targeting%20the%20gut%20microbiota%20to%20enhance%20the%20antitumor%20efficacy%20and%20attenuate%20the%20toxicity%20of%20CAR-T%20cell%20therapy:%20a%20new%20hope?&amp;author=P-F%20Zhang&amp;author=D.%20Xie&amp;volume=15&amp;publication_year=2024&amp;pages=1362133&amp;pmid=38558812&amp;doi=10.3389/fimmu.2024.1362133&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr74-17588359251363207">
<span class="label">74.</span><cite>
Stein-Thoeringer CK, Saini NY, Zamir E, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med
2023; 29: 906–916.
</cite> [<a href="https://doi.org/10.1038/s41591-023-02234-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10121864/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36914893/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=A%20non-antibiotic-disrupted%20gut%20microbiome%20is%20associated%20with%20clinical%20responses%20to%20CD19-CAR-T%20cell%20cancer%20immunotherapy&amp;author=CK%20Stein-Thoeringer&amp;author=NY%20Saini&amp;author=E%20Zamir&amp;volume=29&amp;publication_year=2023&amp;pages=906-916&amp;pmid=36914893&amp;doi=10.1038/s41591-023-02234-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr75-17588359251363207">
<span class="label">75.</span><cite>
Rangan P, Mondino A.
Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy. J Immunother Cancer
2022; 10: e004147.</cite> [<a href="https://doi.org/10.1136/jitc-2021-004147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9330349/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35882448/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Microbial%20short-chain%20fatty%20acids:%20a%20strategy%20to%20tune%20adoptive%20T%20cell%20therapy&amp;author=P%20Rangan&amp;author=A.%20Mondino&amp;volume=10&amp;publication_year=2022&amp;pmid=35882448&amp;doi=10.1136/jitc-2021-004147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr76-17588359251363207">
<span class="label">76.</span><cite>
Prasad R, Rehman A, Rehman L, et al. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood
2025; 145(8): 823–839.
</cite> [<a href="https://doi.org/10.1182/blood.2024025366" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39441941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Antibiotic-induced%20loss%20of%20gut%20microbiome%20metabolic%20output%20correlates%20with%20clinical%20responses%20to%20CAR%20T-cell%20therapy&amp;author=R%20Prasad&amp;author=A%20Rehman&amp;author=L%20Rehman&amp;volume=145&amp;issue=8&amp;publication_year=2025&amp;pages=823-839&amp;pmid=39441941&amp;doi=10.1182/blood.2024025366&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr77-17588359251363207">
<span class="label">77.</span><cite>
Uribe-Herranz M, Beghi S, Ruella M, et al. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. Mol Ther
2023; 31: 686–700.
</cite> [<a href="https://doi.org/10.1016/j.ymthe.2023.01.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10014349/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36641624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Ther&amp;title=Modulation%20of%20the%20gut%20microbiota%20engages%20antigen%20cross-presentation%20to%20enhance%20antitumor%20effects%20of%20CAR%20T%20cell%20immunotherapy&amp;author=M%20Uribe-Herranz&amp;author=S%20Beghi&amp;author=M%20Ruella&amp;volume=31&amp;publication_year=2023&amp;pages=686-700&amp;pmid=36641624&amp;doi=10.1016/j.ymthe.2023.01.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr78-17588359251363207">
<span class="label">78.</span><cite>
Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, et al. Central nervous system demyelinating disease protection by the human commensal <em>Bacteroides fragilis</em> depends on polysaccharide A expression. J Immunol
2010; 185: 4101–4108.
</cite> [<a href="https://doi.org/10.4049/jimmunol.1001443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20817872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunol&amp;title=Central%20nervous%20system%20demyelinating%20disease%20protection%20by%20the%20human%20commensal%20Bacteroides%20fragilis%20depends%20on%20polysaccharide%20A%20expression&amp;author=J%20Ochoa-Rep%C3%A1raz&amp;author=DW%20Mielcarz&amp;author=LE%20Ditrio&amp;volume=185&amp;publication_year=2010&amp;pages=4101-4108&amp;pmid=20817872&amp;doi=10.4049/jimmunol.1001443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr79-17588359251363207">
<span class="label">79.</span><cite>
Braniste V, Al-Asmakh M, Kowal C, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med
2014; 6: 263ra158.</cite> [<a href="https://doi.org/10.1126/scitranslmed.3009759" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4396848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25411471/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Transl%20Med&amp;title=The%20gut%20microbiota%20influences%20blood-brain%20barrier%20permeability%20in%20mice&amp;author=V%20Braniste&amp;author=M%20Al-Asmakh&amp;author=C%20Kowal&amp;volume=6&amp;publication_year=2014&amp;pmid=25411471&amp;doi=10.1126/scitranslmed.3009759&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr80-17588359251363207">
<span class="label">80.</span><cite>
Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell
2018; 174: 1388–1405.e21.</cite> [<a href="https://doi.org/10.1016/j.cell.2018.08.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30193112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Personalized%20gut%20mucosal%20colonization%20resistance%20to%20empiric%20probiotics%20is%20associated%20with%20unique%20host%20and%20microbiome%20features&amp;author=N%20Zmora&amp;author=G%20Zilberman-Schapira&amp;author=J%20Suez&amp;volume=174&amp;publication_year=2018&amp;pmid=30193112&amp;doi=10.1016/j.cell.2018.08.041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr81-17588359251363207">
<span class="label">81.</span><cite>
Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology
2008; 135: 568–579.e2.</cite> [<a href="https://doi.org/10.1053/j.gastro.2008.04.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18570896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Biostructure%20of%20fecal%20microbiota%20in%20healthy%20subjects%20and%20patients%20with%20chronic%20idiopathic%20diarrhea&amp;author=A%20Swidsinski&amp;author=V%20Loening-Baucke&amp;author=H%20Verstraelen&amp;volume=135&amp;publication_year=2008&amp;pmid=18570896&amp;doi=10.1053/j.gastro.2008.04.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr82-17588359251363207">
<span class="label">82.</span><cite>
De Filippis F, Pellegrini N, Vannini L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut
2016; 65: 1812–1821.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2015-309957" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26416813/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=High-level%20adherence%20to%20a%20Mediterranean%20diet%20beneficially%20impacts%20the%20gut%20microbiota%20and%20associated%20metabolome&amp;author=F%20De%20Filippis&amp;author=N%20Pellegrini&amp;author=L%20Vannini&amp;volume=65&amp;publication_year=2016&amp;pages=1812-1821&amp;pmid=26416813&amp;doi=10.1136/gutjnl-2015-309957&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr83-17588359251363207">
<span class="label">83.</span><cite>
Yamamoto ML, Maier I, Dang AT, et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res
2013; 73: 4222–4232.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-13-0022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3718495/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23860718/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Intestinal%20bacteria%20modify%20lymphoma%20incidence%20and%20latency%20by%20affecting%20systemic%20inflammatory%20state,%20oxidative%20stress,%20and%20leukocyte%20genotoxicity&amp;author=ML%20Yamamoto&amp;author=I%20Maier&amp;author=AT%20Dang&amp;volume=73&amp;publication_year=2013&amp;pages=4222-4232&amp;pmid=23860718&amp;doi=10.1158/0008-5472.CAN-13-0022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr84-17588359251363207">
<span class="label">84.</span><cite>
Shi Z, Li M, Zhang C, et al. Butyrate-producing <em>Faecalibacterium prausnitzii</em> suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathway. Gut
2025; 74(4): 557–570.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2024-333530" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12013593/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39653411/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Butyrate-producing%20Faecalibacterium%20prausnitzii%20suppresses%20natural%20killer/T-cell%20lymphoma%20by%20dampening%20the%20JAK-STAT%20pathway&amp;author=Z%20Shi&amp;author=M%20Li&amp;author=C%20Zhang&amp;volume=74&amp;issue=4&amp;publication_year=2025&amp;pages=557-570&amp;pmid=39653411&amp;doi=10.1136/gutjnl-2024-333530&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr85-17588359251363207">
<span class="label">85.</span><cite>
Savitri CMA, Fauzia KA, Alfaray RI, et al. Opportunities for <em>Helicobacter pylori</em> eradication beyond conventional antibiotics. Microorganisms
2024; 12: 1986.
</cite> [<a href="https://doi.org/10.3390/microorganisms12101986" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11509656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39458296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microorganisms&amp;title=Opportunities%20for%20Helicobacter%20pylori%20eradication%20beyond%20conventional%20antibiotics&amp;author=CMA%20Savitri&amp;author=KA%20Fauzia&amp;author=RI%20Alfaray&amp;volume=12&amp;publication_year=2024&amp;pages=1986&amp;pmid=39458296&amp;doi=10.3390/microorganisms12101986&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr86-17588359251363207">
<span class="label">86.</span><cite>
Verma J, Anwar MT, Linz B, et al. The influence of gastric microbiota and probiotics in <em>Helicobacter pylori</em> infection and associated diseases. Biomedicines
2024; 13: 61.
</cite> [<a href="https://doi.org/10.3390/biomedicines13010061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11761556/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39857645/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=The%20influence%20of%20gastric%20microbiota%20and%20probiotics%20in%20Helicobacter%20pylori%20infection%20and%20associated%20diseases&amp;author=J%20Verma&amp;author=MT%20Anwar&amp;author=B%20Linz&amp;volume=13&amp;publication_year=2024&amp;pages=61&amp;pmid=39857645&amp;doi=10.3390/biomedicines13010061&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr87-17588359251363207">
<span class="label">87.</span><cite>
Mehta A, Rangarajan S, Borate U.
A cautionary tale for probiotic use in hematopoietic SCT patients—<em>Lactobacillus acidophilus</em> sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. Bone Marrow Transplant
2013; 48: 461–462.
</cite> [<a href="https://doi.org/10.1038/bmt.2012.153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22890287/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bone%20Marrow%20Transplant&amp;title=A%20cautionary%20tale%20for%20probiotic%20use%20in%20hematopoietic%20SCT%20patients%E2%80%94Lactobacillus%20acidophilus%20sepsis%20in%20a%20patient%20with%20mantle%20cell%20lymphoma%20undergoing%20hematopoietic%20SCT&amp;author=A%20Mehta&amp;author=S%20Rangarajan&amp;author=U.%20Borate&amp;volume=48&amp;publication_year=2013&amp;pages=461-462&amp;pmid=22890287&amp;doi=10.1038/bmt.2012.153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr88-17588359251363207">
<span class="label">88.</span><cite>
Ledoux D, Labombardi VJ, Karter D.
<em>Lactobacillus acidophilus</em> bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin’s disease. Int J STD AIDS
2006; 17: 280–282.
</cite> [<a href="https://doi.org/10.1258/095646206776253507" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16595054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20STD%20AIDS&amp;title=Lactobacillus%20acidophilus%20bacteraemia%20after%20use%20of%20a%20probiotic%20in%20a%20patient%20with%20AIDS%20and%20Hodgkin%E2%80%99s%20disease&amp;author=D%20Ledoux&amp;author=VJ%20Labombardi&amp;author=D.%20Karter&amp;volume=17&amp;publication_year=2006&amp;pages=280-282&amp;pmid=16595054&amp;doi=10.1258/095646206776253507&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr89-17588359251363207">
<span class="label">89.</span><cite>
Yoon SE, Kang W, Chalita M, et al. Comprehensive understanding of gut microbiota in treatment naïve diffuse large B cell lymphoma patients. Blood
2021; 138: 2409.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Comprehensive%20understanding%20of%20gut%20microbiota%20in%20treatment%20na%C3%AFve%20diffuse%20large%20B%20cell%20lymphoma%20patients&amp;author=SE%20Yoon&amp;author=W%20Kang&amp;author=M%20Chalita&amp;volume=138&amp;publication_year=2021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr90-17588359251363207">
<span class="label">90.</span><cite>
Imataki O, Uemura M.
Bifidobacterium bloodstream infection in a lymphoma patient undergoing chemotherapy: a case study and implications for probiotic use. Am J Case Rep
2024; 25: e944687.</cite> [<a href="https://doi.org/10.12659/AJCR.944687" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11351929/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39180199/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Case%20Rep&amp;title=Bifidobacterium%20bloodstream%20infection%20in%20a%20lymphoma%20patient%20undergoing%20chemotherapy:%20a%20case%20study%20and%20implications%20for%20probiotic%20use&amp;author=O%20Imataki&amp;author=M.%20Uemura&amp;volume=25&amp;publication_year=2024&amp;pmid=39180199&amp;doi=10.12659/AJCR.944687&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr91-17588359251363207">
<span class="label">91.</span><cite>
Miller LE, Zimmermann AK, Ouwehand AC.
Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit. World J Gastroenterol
2016; 22: 5122–5131.
</cite> [<a href="https://doi.org/10.3748/wjg.v22.i21.5122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4886388/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27275105/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Gastroenterol&amp;title=Contemporary%20meta-analysis%20of%20short-term%20probiotic%20consumption%20on%20gastrointestinal%20transit&amp;author=LE%20Miller&amp;author=AK%20Zimmermann&amp;author=AC.%20Ouwehand&amp;volume=22&amp;publication_year=2016&amp;pages=5122-5131&amp;pmid=27275105&amp;doi=10.3748/wjg.v22.i21.5122&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr92-17588359251363207">
<span class="label">92.</span><cite>
Montassier E, Batard E, Massart S, et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol
2014; 67: 690–699.
</cite> [<a href="https://doi.org/10.1007/s00248-013-0355-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24402367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microb%20Ecol&amp;title=16S%20rRNA%20gene%20pyrosequencing%20reveals%20shift%20in%20patient%20faecal%20microbiota%20during%20high-dose%20chemotherapy%20as%20conditioning%20regimen%20for%20bone%20marrow%20transplantation&amp;author=E%20Montassier&amp;author=E%20Batard&amp;author=S%20Massart&amp;volume=67&amp;publication_year=2014&amp;pages=690-699&amp;pmid=24402367&amp;doi=10.1007/s00248-013-0355-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr93-17588359251363207">
<span class="label">93.</span><cite>
Ghani R, Chrysostomou D, Roberts LA, et al. Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome. Gut Microbes
2024; 16: 2423026.
</cite> [<a href="https://doi.org/10.1080/19490976.2024.2423026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11540080/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39499189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut%20Microbes&amp;title=Faecal%20(or%20intestinal)%20microbiota%20transplant:%20a%20tool%20for%20repairing%20the%20gut%20microbiome&amp;author=R%20Ghani&amp;author=D%20Chrysostomou&amp;author=LA%20Roberts&amp;volume=16&amp;publication_year=2024&amp;pages=2423026&amp;pmid=39499189&amp;doi=10.1080/19490976.2024.2423026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr94-17588359251363207">
<span class="label">94.</span><cite>
Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood
2016; 128: 2083–2088.
</cite> [<a href="https://doi.org/10.1182/blood-2016-05-717652" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5085256/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27461930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Fecal%20microbiota%20transplantation%20for%20patients%20with%20steroid-resistant%20acute%20graft-versus-host%20disease%20of%20the%20gut&amp;author=K%20Kakihana&amp;author=Y%20Fujioka&amp;author=W%20Suda&amp;volume=128&amp;publication_year=2016&amp;pages=2083-2088&amp;pmid=27461930&amp;doi=10.1182/blood-2016-05-717652&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr95-17588359251363207">
<span class="label">95.</span><cite>
DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant <em>E. coli</em> bacteremia transmitted by fecal microbiota transplant. N Engl J Med
2019; 381: 2043–2050.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1910437" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31665575/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Drug-resistant%20E.%20coli%20bacteremia%20transmitted%20by%20fecal%20microbiota%20transplant&amp;author=Z%20DeFilipp&amp;author=PP%20Bloom&amp;author=M%20Torres%20Soto&amp;volume=381&amp;publication_year=2019&amp;pages=2043-2050&amp;pmid=31665575&amp;doi=10.1056/NEJMoa1910437&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr96-17588359251363207">
<span class="label">96.</span><cite>
Yoo JY, Groer M, Dutra SVO, et al. Gut microbiota and immune system interactions. Microorganisms
2020; 8: 1587.</cite> [<a href="https://doi.org/10.3390/microorganisms8101587" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7602490/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33076307/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microorganisms&amp;title=Gut%20microbiota%20and%20immune%20system%20interactions&amp;author=JY%20Yoo&amp;author=M%20Groer&amp;author=SVO%20Dutra&amp;volume=8&amp;publication_year=2020&amp;pmid=33076307&amp;doi=10.3390/microorganisms8101587&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr97-17588359251363207">
<span class="label">97.</span><cite>
Benech N, Cassir N, Galperine T, et al. Fecal microbiota transplantation for recurrent <em>Clostridioides difficile</em> infection can be the best therapeutic option in severely immunocompromised patients depending on a case-by-case assessment of the benefit-to-risk ratio. Gastroenterology
2024; 167: 627–628.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2024.04.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38679396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Fecal%20microbiota%20transplantation%20for%20recurrent%20Clostridioides%20difficile%20infection%20can%20be%20the%20best%20therapeutic%20option%20in%20severely%20immunocompromised%20patients%20depending%20on%20a%20case-by-case%20assessment%20of%20the%20benefit-to-risk%20ratio&amp;author=N%20Benech&amp;author=N%20Cassir&amp;author=T%20Galperine&amp;volume=167&amp;publication_year=2024&amp;pages=627-628&amp;pmid=38679396&amp;doi=10.1053/j.gastro.2024.04.022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr98-17588359251363207">
<span class="label">98.</span><cite>
Hays KE, Pfaffinger JM, Ryznar R.
The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease. Gut Microbes
2024; 16: 2393270.
</cite> [<a href="https://doi.org/10.1080/19490976.2024.2393270" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11407412/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39284033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut%20Microbes&amp;title=The%20interplay%20between%20gut%20microbiota,%20short-chain%20fatty%20acids,%20and%20implications%20for%20host%20health%20and%20disease&amp;author=KE%20Hays&amp;author=JM%20Pfaffinger&amp;author=R.%20Ryznar&amp;volume=16&amp;publication_year=2024&amp;pages=2393270&amp;pmid=39284033&amp;doi=10.1080/19490976.2024.2393270&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr99-17588359251363207">
<span class="label">99.</span><cite>
Cristiano C, Cuozzo M, Coretti L, et al. Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction. Biomed Pharmacother
2022; 153: 113528.
</cite> [<a href="https://doi.org/10.1016/j.biopha.2022.113528" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36076609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomed%20Pharmacother&amp;title=Oral%20sodium%20butyrate%20supplementation%20ameliorates%20paclitaxel-induced%20behavioral%20and%20intestinal%20dysfunction&amp;author=C%20Cristiano&amp;author=M%20Cuozzo&amp;author=L%20Coretti&amp;volume=153&amp;publication_year=2022&amp;pages=113528&amp;pmid=36076609&amp;doi=10.1016/j.biopha.2022.113528&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bibr100-17588359251363207">
<span class="label">100.</span><cite>
Fang W, Xue H, Chen X, et al. Supplementation with sodium butyrate modulates the composition of the gut microbiota and ameliorates high-fat diet-induced obesity in mice. J Nutr
2019; 149: 747–754.
</cite> [<a href="https://doi.org/10.1093/jn/nxy324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31004166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Nutr&amp;title=Supplementation%20with%20sodium%20butyrate%20modulates%20the%20composition%20of%20the%20gut%20microbiota%20and%20ameliorates%20high-fat%20diet-induced%20obesity%20in%20mice&amp;author=W%20Fang&amp;author=H%20Xue&amp;author=X%20Chen&amp;volume=149&amp;publication_year=2019&amp;pages=747-754&amp;pmid=31004166&amp;doi=10.1093/jn/nxy324&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Therapeutic Advances in Medical Oncology are provided here courtesy of <strong>SAGE Publications</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1177/17588359251363207"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/10.1177_17588359251363207.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (893.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12365434/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12365434/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12365434%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12365434/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12365434/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12365434/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40842975/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12365434/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40842975/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12365434/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12365434/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="UirEkUPy130QNDRYpUwNeHlMPurBm4wMRcStj85p0SwE5l9tgFxB0pNyODO5sjx2">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
